Details of Disease

General Information of Disease (ID: DISQCIRF)

Disease Name Chronic obstructive pulmonary disease
Synonyms
chronic obstructive pulmonary disease, (COPD); cold; obstructive lung disease, chronic; chronic obstructive lung disease; chronic obstructive airways disease; cold (chronic obstructive lung disease); chronic obstructive airway disease; COPD, chronic obstructive pulmonary disease; obstructive pulmonary disease (COPD), chronic; pulmonary disease (COPD), chronic obstructive; disease (COPD), chronic obstructive; chronic obstructive pulmonary disease (COPD); COPD
Disease Class CA22: Chronic obstructive pulmonary disease
Definition
A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.
Disease Hierarchy
DISKMDMR: Tracheal disorder
DIS4IIDZ: Obstructive lung disease
DISQCIRF: Chronic obstructive pulmonary disease
ICD Code
ICD-11
ICD-11: CA22
ICD-10
ICD-10: J40-J44, J47
ICD-9
ICD-9: 490-492, 494-496
Expand ICD-9
4.90E+17
Disease Identifiers
MONDO ID
MONDO_0005002
MESH ID
D029424
UMLS CUI
C0024117
OMIM ID
606963
MedGen ID
9818
HPO ID
HP:0006510
SNOMED CT ID
13645005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 28 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Aclidinium DMW8YQQ Approved Small molecular drug [1]
Almitrine DM0SYAN Approved Small molecular drug [2]
Anoro DMK6W3F Approved NA [3]
Arformoterol DMYM974 Approved Small molecular drug [4]
Bamifylline DMXLHYN Approved Small molecular drug [3]
Benralizumab DM7P1J4 Approved Monoclonal antibody [5]
Bitolterol DMK6XAV Approved Small molecular drug [3]
Carbocisteine DMM44CO Approved Small molecular drug [3]
Fluorometholone DM2HKC4 Approved Small molecular drug [3]
Glycopyrrolate DM2M3ZA Approved Small molecular drug [6]
Incruse Ellipta DM32GSJ Approved Small molecular drug [3]
Indacaterol DMQJHR7 Approved Small molecular drug [7]
LAS-34273 DMSQ1JV Approved Small molecular drug [8]
Maraviroc DMTL94F Approved Small molecular drug [9]
Meprednisone DMTL9IP Approved Small molecular drug [3]
MK-08887A DMBVQL1 Approved Small molecular drug [3]
Olodaterol DM62B78 Approved Small molecular drug [10]
Prasterone DM67VKL Approved Small molecular drug [11]
Pregabalin DMDVP3B Approved Small molecular drug [12]
Revefenacin DMMP5SI Approved NA [13]
Roflumilast DMPGHY8 Approved Small molecular drug [14]
Salmeterol DMIEU69 Approved Small molecular drug [15]
Symbicort DM6L7CL Approved Small molecular drug [16]
Theophylline DMRJFN9 Approved Small molecular drug [17]
Tiotropium DMFDC0Q Approved Small molecular drug [18]
Umeclidinium DM4E8O9 Approved Small molecular drug [19]
Vilanterol DMF5EK1 Approved Small molecular drug [20]
Ozagrel DMIGKA1 Phase 4 Small molecular drug [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Drug(s)
This Disease is Treated as An Indication in 93 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Arofylline DM84AD1 Phase 3 Small molecular drug [22]
Astegolimab DMKOHC5 Phase 3 Monoclonal antibody [23]
Bococizumab DM2OBNW Phase 3 Antibody [24]
GSK642444 DMUVZAO Phase 3 Small molecular drug [25]
Itepekimab DMR8NDD Phase 3 Antibody [26]
Lebrikizumab DMQP0X5 Phase 3 Monoclonal antibody [27]
MEDI3506 DMDI7SA Phase 3 Antibody [28]
PT001 GP DM986RW Phase 3 NA [29]
PT003 DMSTXU0 Phase 3 NA [30]
PT005 DMTSN8L Phase 3 Small molecular drug [30]
QMF149 DMTY70Q Phase 3 NA [31]
QVA-149 DMSFX75 Phase 3 Small molecular drug [32]
SAR440340 DMKYXSS Phase 3 Antibody [26]
SUN-101 DMXNZQK Phase 3 NA [33]
Tozorakimab DMCXN80 Phase 3 Monoclonal antibody [28]
Mitiperstat DM0BL2G Phase 2/3 Small molecule [34]
OrM3 DMEARCM Phase 2b NA [25]
Bimosiamose DM0TH9A Phase 2a Small molecular drug [35]
AER-002 DM1MUR7 Phase 2 NA [36]
AQX-1125 DMCH3G5 Phase 2 Small molecular drug [37]
AZD-2115 DMGQSVX Phase 2 NA [38]
AZD-2423 DMF34UY Phase 2 Small molecular drug [39]
AZD-8683 DMLXFM6 Phase 2 NA [40]
AZD-9164 DMVKPEZ Phase 2 NA [41]
AZD1981 DMMCL9F Phase 2 Small molecular drug [42]
AZD7594 DMNE3UQ Phase 2 NA [43]
AZD7624 DMEW3K9 Phase 2 NA [44]
AZD8871 DMQKFM4 Phase 2 Small molecule [45]
AZD9056 DMJGYPK Phase 2 Small molecular drug [46]
AZD9668 DMB87M3 Phase 2 Small molecular drug [47]
BCT-197 DMPB40F Phase 2 NA [48]
BIO-11006 DM6N05H Phase 2 NA [49]
Carmoterol DMN6TKI Phase 2 Small molecular drug [50]
CSJ117 DMZJUV6 Phase 2 Antibody [51]
DS102 DM1K3ER Phase 2 NA [52]
EP-101 DM69NF1 Phase 2 Small molecular drug [53]
GSK1325756 DMA6RBF Phase 2 Small molecular drug [54]
GSK2245840 DMG7YQL Phase 2 Small molecular drug [55]
GSK233705 DMXUCG3 Phase 2 NA [25]
GSK961081 DM6DKF9 Phase 2 Small molecular drug [56]
GSP 304 DM7Q93M Phase 2 NA [57]
Haemophilus recombinant vaccine DMW7XWD Phase 2 NA [58]
IC-485 DMB1UYV Phase 2 Small molecular drug [22]
Igmesine DMH97XA Phase 2 Small molecular drug [22]
Interferon-alpha lozenge DM8YF01 Phase 2 NA [59]
JNJ-10311795 DM7OTQS Phase 2 Small molecular drug [60]
Lancovutide DM7MBV6 Phase 2 NA [61]
LAS 100977 DMPRZX4 Phase 2 Small molecular drug [62]
LIRIMILAST DMD4KAU Phase 2 Small molecular drug [63]
O-desulfated heparin DMJL4A7 Phase 2 NA [64]
ODSH DMNIPLQ Phase 2 NA [65]
ONO-6126 DMRT28X Phase 2 Small molecular drug [22]
PF-03715455 DMAMLUT Phase 2 Small molecular drug [66]
PF-3635659 DMHJXEE Phase 2 Small molecular drug [67]
PF-489791 DM3C8GQ Phase 2 Small molecular drug [68]
PH-797804 DMH6KYI Phase 2 Small molecular drug [69]
PS-938285 DMHZIFJ Phase 2 NA [70]
QAX-028 DMXY0H2 Phase 2 NA [71]
QBM076 DMXAK10 Phase 2 NA [72]
QBW251 DMQ5APT Phase 2 Small molecule [73]
SB-265610 DM8TKG5 Phase 2 Small molecular drug [22]
SB-656933 DMCY785 Phase 2 Small molecular drug [74]
SCH-527123 DMPUAOE Phase 2 Small molecular drug [75]
SelK2 DMM6B6E Phase 2 Antibody [76]
TA-2005 DMMWPSQ Phase 2 Small molecular drug [22]
Tetomilast DMCUGNY Phase 2 Small molecular drug [77]
THRX-198321 DM1BYNF Phase 2 NA [78]
TOFIMILAST DMLCUAS Phase 2 Small molecular drug [79]
TPI-1020 DMSA2LZ Phase 2 NA [80]
TRN-157 DM64NYP Phase 2 NA [81]
UK-432097 DM2O4MI Phase 2 Small molecular drug [82]
Vasoactive intestinal peptide DMRJ5LP Phase 2 Small molecular drug [83]
YPL-001 DMHDI8H Phase 2 NA [84]
Zofin DMN9W53 Phase 1/2 NA [85]
AZD-2551 DMZQEDY Phase 1 NA [86]
AZD-5122 DMQEO4V Phase 1 NA [87]
AZD-9819 DMWYHXG Phase 1 NA [88]
AZD4721 DM36EY7 Phase 1 NA [89]
BI 1323495 DMAUKTS Phase 1 NA [90]
BI-137882 DMC8RVX Phase 1 NA [91]
CCI 15106 DMUHZLZ Phase 1 NA [92]
CHF 5407 DMSDNU1 Phase 1 NA [25]
Dexpirronium DMAE9I0 Phase 1 NA [93]
GSK2256294 DM7FN12 Phase 1 NA [94]
GSK3923868 DMLDJ31 Phase 1 Small molecule [95]
MEDI-2338 DMCMYPX Phase 1 NA [96]
MEDI7814 DM8BXDI Phase 1 NA [97]
POL-6014 DM9B68S Phase 1 NA [98]
PUR0200 DMX5LB7 Phase 1 NA [99]
PUR1800 DM6H10N Phase 1 Small molecule [100]
QAK-423 DMMWOVR Phase 1 NA [101]
RG-7103 DM2IDQ9 Phase 1 NA [102]
Ronomilast DM82KWY Phase 1 Small molecular drug [103]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 Drug(s)
This Disease is Treated as An Indication in 4 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID27998201-Compound-5 DMVZ0ND Patented Small molecular drug [104]
Quinazoline derivative 10 DMZ3ORT Patented Small molecular drug [105]
Quinazoline derivative 11 DMAH435 Patented Small molecular drug [105]
Quinazoline derivative 12 DMVKZU2 Patented Small molecular drug [105]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 48 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Levcromakalim DMNS4TK Discontinued in Preregistration Small molecular drug [106]
Telenzepine DM6PVWS Discontinued in Preregistration Small molecular drug [107]
Cilomilast DMHSM7I Discontinued in Phase 3 Small molecular drug [108]
Sibenadet DMYQT2V Discontinued in Phase 3 Small molecular drug [109]
AZD-5423 DME8KQW Discontinued in Phase 2 Small molecular drug [110]
AZD1236 DML3RSF Discontinued in Phase 2 Small molecular drug [111]
AZD4818 DM3VFKM Discontinued in Phase 2 Small molecular drug [112]
BRL-55834 DM0WG4U Discontinued in Phase 2 Small molecular drug [113]
CDP840 DMUPJW4 Discontinued in Phase 2 Small molecular drug [114]
CE-1037 DM746L8 Discontinued in Phase 2 Small molecular drug [115]
CS-003 DM1AEVT Discontinued in Phase 2 Small molecular drug [22]
Darotropium DMJ4WR6 Discontinued in Phase 2 NA [116]
EPI-12323 DMLIB1X Discontinued in Phase 2 NA [117]
Filaminast DMGD5QN Discontinued in Phase 2 Small molecular drug [118]
GSK-159797 DMTZBXQ Discontinued in Phase 2 Small molecular drug [22]
KCO-912 DMC30N4 Discontinued in Phase 2 NA [119]
MLN-977 DMTWLG8 Discontinued in Phase 2 Small molecular drug [120]
PF-610355 DM6XEQA Discontinued in Phase 2 NA [121]
Rispenzepine DMVHT6F Discontinued in Phase 2 Small molecular drug [122]
Tolafentrine DMEROU4 Discontinued in Phase 2 Small molecular drug [123]
WC-3027 DMLA4DU Discontinued in Phase 2 NA [124]
AE-3763 DMRSEZD Discontinued in Phase 1 Small molecular drug [125]
AZD-2315 DMG9HM8 Discontinued in Phase 1 NA [126]
AZD-3342 DMUCQPB Discontinued in Phase 1 NA [127]
AZD-4407 DM7XQTM Discontinued in Phase 1 NA [128]
AZD-6553 DMQZCET Discontinued in Phase 1 NA [129]
AZD-7140 DMX63W1 Discontinued in Phase 1 NA [130]
AZD-8309 DMW6IUB Discontinued in Phase 1 NA [131]
AZD5904 DM8SCON Discontinued in Phase 1 Small molecular drug [132]
AZD5985 DMCAKMV Discontinued in Phase 1 Small molecular drug [133]
AZD8075 DMKF9U3 Discontinued in Phase 1 NA [134]
AZD8566 DMIYEZG Discontinued in Phase 1 NA [135]
FR167653 DM69OR8 Discontinued in Phase 1 Small molecular drug [136]
QAN-747 DMR0D9K Discontinued in Phase 1 NA [137]
Revatropate DMT5VXF Discontinued in Phase 1 Small molecular drug [22]
Rilmakalim DMBQZTO Discontinued in Phase 1 Small molecular drug [138]
SB-332235 DM57HZW Discontinued in Phase 1 Small molecular drug [139]
SCH-351591 DMK40VO Discontinued in Phase 1 Small molecular drug [140]
ZD-0892 DM82V1D Discontinued in Phase 1 Small molecular drug [141]
AD-313 DM9ZLCN Terminated NA [144]
AR-C-89855 DM9HZ8D Terminated NA [145]
AZD-0275 DMJH7IX Terminated NA [146]
AZD-0902 DMS7INR Terminated NA [147]
AZD-2914 DM3PQNG Terminated NA [148]
ML-03 DM5G4WW Terminated NA [149]
NIK-616 DM4U7XB Terminated NA [150]
SSR-69071 DMWL4MI Terminated Small molecular drug [151]
ZARDAVERINE DMC38FO Terminated Small molecular drug [152]
------------------------------------------------------------------------------------
⏷ Show the Full List of 48 Drug(s)
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AZD-7928 DMXCFJ6 Preclinical NA [142]
GW-3333 DM3PMAZ Preclinical Small molecular drug [22]
RS-504393 DMB9IPR Preclinical Small molecular drug [143]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 25 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ADC-7828 DM19KY6 Investigative NA [98]
ADS-0101 DMP7IS0 Investigative Antibody [153]
AMA-237 DMW9TRD Investigative NA [154]
CDP-146 DMEG6I6 Investigative NA [155]
CHF-5480 DM5T64L Investigative NA [156]
DX-2300 DMMBSE6 Investigative NA [155]
EP-102 DMQVUBU Investigative NA [157]
J-104135 DMAEQS9 Investigative Small molecular drug [158]
MBS-103 DM85JEE Investigative NA [155]
MDT-011 DMD7G7D Investigative NA [155]
MMP-408 DMVCNBH Investigative NA [159]
OT-010 DM0TF4Y Investigative NA [155]
PD-3766 DM2O026 Investigative NA [155]
PF-613322 DMON19D Investigative NA [155]
PUP-1 DMCWT4L Investigative NA [159]
PYM-60001 DMP292P Investigative NA [155]
RBx-343E48F0 DMNEK79 Investigative NA [160]
SOM-0525 DMX6ORW Investigative NA [155]
SOM-1033 DMNK11M Investigative NA [155]
TRN-101 DMXNSTF Investigative NA [154]
UR-5908 DMLJA8K Investigative NA [155]
X-072-NAB DMS4XJ1 Investigative NA [155]
YPL-1101 DM1WQO0 Investigative NA [155]
ZP-003 DMDDBPI Investigative NA [155]
ZP-013 DM8YMDE Investigative NA [155]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 315 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ACLY TT0Z6Y2 Limited Biomarker [167]
ACTG1 TTGAZF9 Limited Genetic Variation [168]
ALPI TTHYMUV Limited Biomarker [169]
ANO1 TTOJI4S Limited Altered Expression [170]
ATP2A2 TTE6THL Limited Biomarker [171]
AZGP1 TTUPYLV Limited Altered Expression [172]
BPI TTXCSDR Limited Biomarker [173]
CARM1 TTIZQFJ Limited Biomarker [174]
CCL22 TTBTWI1 Limited Biomarker [175]
CCR2 TTFZYTO Limited Biomarker [176]
CD1A TTBGTFN Limited Biomarker [177]
CDH11 TTRGWZC Limited Genetic Variation [178]
CDH3 TTARMD9 Limited Altered Expression [179]
CXCL10 TTQOVYA Limited Altered Expression [180]
DEPTOR TTLYP6D Limited Altered Expression [181]
DIO1 TTU3X26 Limited Biomarker [182]
DNASE1 TTYWGOJ Limited Biomarker [183]
FHL1 TTI7ENL Limited Biomarker [184]
FKBP5 TT0J5KQ Limited Genetic Variation [185]
FPR1 TT5Y4EM Limited Altered Expression [186]
FPR2 TTOJ1NF Limited Biomarker [186]
FTO TTFW3BT Limited Genetic Variation [187]
GALNS TTT9YPO Limited Altered Expression [188]
GRIK2 TT0K5RG Limited Altered Expression [189]
GSR TTEP6RV Limited Genetic Variation [190]
GSTO1 TTWO3SH Limited Altered Expression [191]
HBEGF TT15SL0 Limited Biomarker [192]
HDAC7 TTMUEK1 Limited Genetic Variation [178]
HMGA2 TTSTVM0 Limited Genetic Variation [178]
HMOX1 TTI6V2A Limited Unknown [193]
HTR2B TT0K1SC Limited Biomarker [194]
HTR4 TT07C3Y Limited Genetic Variation [195]
IDS TTNY2AP Limited Altered Expression [188]
IFNL3 TTRF4Q2 Limited Genetic Variation [196]
IL15RA TTGN89I Limited Biomarker [197]
IL31RA TT9HPX0 Limited Biomarker [198]
IL33 TT5MD4P Limited Biomarker [199]
INPP5D TTTP2Z1 Limited Biomarker [200]
KLK6 TTLPF4X Limited Biomarker [201]
LBP TTVQJLY Limited Altered Expression [202]
LTB4R TTN53ZF Limited Biomarker [203]
NFKB1 TTUIZKC Limited Genetic Variation [204]
NQO1 TT8XK6L Limited Therapeutic [205]
NR3C2 TT26PHO Limited Altered Expression [206]
NR4A3 TTJQB49 Limited Altered Expression [207]
OAT TTTSCQ2 Limited Altered Expression [189]
PAK2 TT279WO Limited Altered Expression [208]
PKN2 TTTHO0M Limited Genetic Variation [178]
PLA2G4C TTBYG4O Limited Biomarker [209]
PTAFR TTQL5VC Limited Biomarker [210]
RAPGEF3 TTOE7I0 Limited Altered Expression [211]
REG3A TTL4H8N Limited Biomarker [212]
RIPK2 TTCQ2E5 Limited Biomarker [213]
RPGR TTHBDA9 Limited Biomarker [214]
SGSH TTPJ2SH Limited Altered Expression [188]
SLC2A4 TTP6MT5 Limited Altered Expression [215]
SPDEF TT2ZUPY Limited Altered Expression [216]
STC2 TT4EFTR Limited Altered Expression [217]
TACR2 TTYO0A3 Limited Altered Expression [218]
TMEM219 TTY078U Limited Genetic Variation [178]
TREM2 TTQRMSJ Limited Biomarker [219]
TRPC3 TTNVC34 Limited Altered Expression [220]
TRPV2 TTBECWA Limited Biomarker [221]
TUSC2 TTJ8O14 Limited Biomarker [212]
YY1AP1 TTYED1Q Limited Altered Expression [222]
GLP1R TTVIMDE Disputed Biomarker [223]
HDAC3 TT4YWTO Disputed Biomarker [224]
PTPN1 TTELIN2 Disputed Altered Expression [225]
ABCA4 TTLB52K moderate Biomarker [226]
ADAM9 TTTYQNS moderate Altered Expression [227]
ADCY2 TTBQ9IM moderate Genetic Variation [228]
ADORA2B TTNE7KG moderate Altered Expression [229]
ADRB1 TTR6W5O moderate Biomarker [230]
AOC3 TT7HC21 moderate Altered Expression [231]
ARSB TTESQTG moderate Altered Expression [232]
ATF3 TTCE793 moderate Biomarker [233]
ATF4 TTQCKWT moderate Biomarker [234]
BMPR2 TTGKF90 moderate Genetic Variation [235]
CASP3 TTPF2QI moderate Biomarker [236]
CCL20 TT2XAZY moderate Biomarker [237]
CD83 TTT9MRQ moderate Altered Expression [238]
CHRM2 TTYEG6Q moderate Genetic Variation [239]
CHRNA1 TT54JVQ moderate Genetic Variation [240]
CHRNA7 TTLA931 moderate Biomarker [241]
CHRNB4 TTTVAFQ moderate Genetic Variation [195]
CHUK TT1F8OQ moderate Biomarker [242]
CLCA1 TT3AF4R moderate Biomarker [243]
CS TTZA6B3 moderate Altered Expression [244]
CTH TTLQUZS moderate Biomarker [245]
CTSE TTLXC4Q moderate Biomarker [246]
CX3CL1 TT1OFBQ moderate Biomarker [247]
CXCL1 TTLK1RW moderate Biomarker [211]
CXCL11 TTWG0RE moderate Altered Expression [248]
CYP3A5 TTHS0OK moderate Genetic Variation [249]
DBH TTYIP79 moderate Biomarker [250]
DOT1L TTSZ8T1 moderate Altered Expression [251]
EIF2AK3 TT79U1M moderate Biomarker [252]
ELK3 TT5OJMV moderate Biomarker [253]
EPHB1 TT8MDAC moderate Biomarker [253]
EPHX2 TT7WVHI moderate Biomarker [254]
ETS2 TT9AH0M moderate Biomarker [255]
FCGR1A TTZK4I3 moderate Altered Expression [256]
FDPS TTIKWV4 moderate Biomarker [257]
FES TTLBY21 moderate Biomarker [257]
FGL2 TTYBS89 moderate Biomarker [258]
FURIN TTH9WF6 moderate Biomarker [259]
GALC TT5IZRB moderate Genetic Variation [260]
GPR182 TTT23CG moderate Altered Expression [261]
GSS TTVEWR4 moderate Genetic Variation [262]
HCK TT42OGM moderate Genetic Variation [263]
HDAC5 TTUELN5 moderate Biomarker [264]
HOXA11 TTEX4ZA moderate Genetic Variation [265]
HOXA13 TTN26OM moderate Genetic Variation [265]
HOXA5 TTXSVQP moderate Genetic Variation [265]
HOXA7 TTMRE4Q moderate Genetic Variation [265]
HSD11B1 TTN7BL9 moderate Biomarker [266]
IFNL1 TTM624L moderate Altered Expression [267]
IL12A TTRTK6Y moderate Genetic Variation [268]
IL12B TTGW72V moderate Genetic Variation [268]
IL13RA1 TTNEAMG moderate Genetic Variation [269]
IL1RAP TTWS50K moderate Biomarker [270]
IL1RL1 TT4GZA4 moderate Biomarker [271]
IRAK1 TTXAJWN moderate Biomarker [272]
IRAK4 TTILUKB moderate Biomarker [272]
ITGA5 TTHIZP9 moderate Biomarker [273]
ITGAL TT48WR6 moderate Biomarker [274]
KCNJ2 TTH7UO3 moderate Genetic Variation [275]
KLK1 TT5T3P6 moderate Altered Expression [276]
KLKB1 TTN0PCX moderate Genetic Variation [277]
KNG1 TTDJ4MY moderate Genetic Variation [278]
LAMP1 TTC214J moderate Altered Expression [279]
MAPK7 TTU6FSC moderate Posttranslational Modification [280]
MARK2 TTAJ45Y moderate Genetic Variation [281]
MBTPS1 TTNSM2I moderate Biomarker [282]
MFGE8 TT1GLAJ moderate Altered Expression [283]
MIA TT5HNVS moderate Genetic Variation [284]
NLRX1 TTKT026 moderate Biomarker [285]
P2RX1 TTJW7B3 moderate Biomarker [286]
P2RX3 TT2THBD moderate Biomarker [286]
P2RX4 TT1NLOA moderate Biomarker [286]
P2RY1 TTA93TL moderate Biomarker [286]
P2RY2 TTOZHQC moderate Altered Expression [287]
PAH TTGSVH2 moderate Genetic Variation [288]
PDE4B TTVIAT9 moderate Altered Expression [289]
PDE7A TT1BC3A moderate Biomarker [290]
PIM2 TT69J2Z moderate Genetic Variation [291]
PRKCZ TTBSN0L moderate Biomarker [237]
RORA TT1TYN7 moderate Biomarker [292]
RORC TTGV6LY moderate Biomarker [293]
RPS6KA5 TTYXEPL moderate Biomarker [294]
RRM1 TTWP0NS moderate Genetic Variation [262]
S1PR2 TTVSMOH moderate Biomarker [282]
S1PR5 TTDZCKV moderate Biomarker [295]
SCARB1 TTRE324 moderate Altered Expression [266]
SERPINE1 TTTO43N moderate Biomarker [296]
SERPING1 TTVQ6R9 moderate Biomarker [297]
SETD7 TTJ0FSU moderate Genetic Variation [298]
SGCA TTS9Q5V moderate Genetic Variation [299]
SGPL1 TT618Q2 moderate Biomarker [282]
SIRT6 TTUXYWF moderate Altered Expression [300]
SLC22A12 TTA592U moderate Altered Expression [301]
SLC6A2 TTAWNKZ moderate Biomarker [253]
SOX5 TTXHSZK moderate Genetic Variation [302]
SRC TT6PKBN moderate Biomarker [303]
SRR TTZFUY6 moderate Biomarker [304]
SUV39H1 TTUWQTK moderate Altered Expression [305]
SVIL TTBLQS5 moderate Genetic Variation [306]
TBK1 TTMP03S moderate Biomarker [307]
TLR8 TT8CWFK moderate Biomarker [308]
TNFRSF4 TTL31H0 moderate Altered Expression [309]
TNNT2 TTWAS18 moderate Altered Expression [310]
TPP1 TTOVYPT moderate Biomarker [311]
TRPC1 TTA76X0 moderate Altered Expression [312]
TXNRD1 TTR7UJ3 moderate Altered Expression [313]
TXNRD3 TTDYFVB moderate Biomarker [314]
UGCG TTPHEX3 moderate Biomarker [315]
ULK1 TT4D7MJ moderate Biomarker [316]
VIPR1 TTCL30I moderate Altered Expression [317]
WDR5 TT7OFWB moderate Biomarker [318]
ABCA1 TTJW1GN Strong Altered Expression [319]
ADAM8 TTQWYMD Strong Altered Expression [320]
ADCY5 TTN64VU Strong Genetic Variation [195]
ADORA2A TTM2AOE Strong Altered Expression [321]
ADRB2 TTG8ZWP Strong Biomarker [322]
AGER TTMO9HF Strong Genetic Variation [195]
AHCY TTE2KUJ Strong Biomarker [323]
AIMP2 TTXWHGF Strong Altered Expression [324]
ANPEP TTPHMWB Strong Altered Expression [325]
ANXA5 TT2Z83I Strong Genetic Variation [250]
BCHE TT3MSAO Strong Genetic Variation [326]
BMP6 TT07RIB Strong Altered Expression [327]
C3AR1 TTI6B3F Strong Altered Expression [328]
CAMP TTULOB6 Strong Altered Expression [329]
CASP4 TT6KIOT Strong Altered Expression [330]
CASP8 TT6SZNG Strong Therapeutic [331]
CCL11 TTCF05Y Strong Altered Expression [332]
CCN2 TTIL516 Strong Altered Expression [333]
CCR5 TTJIH8Q Strong Altered Expression [334]
CCR6 TTFDB30 Strong Altered Expression [335]
CCR8 TTE836A Strong Altered Expression [336]
CD14 TT6I7DC Strong Genetic Variation [337]
CD163 TTTZ9DE Strong Altered Expression [338]
CD33 TTJVYO3 Strong Genetic Variation [339]
CD80 TT89Z17 Strong Altered Expression [340]
CD96 TT83C4X Strong Genetic Variation [250]
CDC123 TT3PRUG Strong Genetic Variation [195]
CEL TTTRNQW Strong Biomarker [341]
CFH TTUW6OP Strong Genetic Variation [342]
CFLAR TTJZQYH Strong Biomarker [343]
CFTR TTRLZHP Strong Biomarker [344]
CHIT1 TTDYX6T Strong Biomarker [345]
CHRM3 TTQ13Z5 Strong Genetic Variation [195]
CHRNA4 TT4H1MQ Strong Altered Expression [346]
CHRNA5 TTH2QRX Strong Genetic Variation [347]
CRK TTFEUYR Strong Altered Expression [324]
CSE1L TTTRULD Strong Genetic Variation [348]
CTSG TTQAJF1 Strong Biomarker [349]
CTSS TTUMQVO Strong Altered Expression [341]
CXCL13 TT0NIZ1 Strong Biomarker [350]
CXCL2 TTZF0K2 Strong Biomarker [351]
CXCR2 TT30C9G Strong Biomarker [352]
CYBB TT5T8MR Strong Altered Expression [353]
CYP1A2 TTS1DTU Strong Genetic Variation [354]
DDX58 TTVB0O3 Strong Altered Expression [355]
DEFB4A TTIVY12 Strong Biomarker [356]
DPP4 TTDIGC1 Strong Altered Expression [357]
EGLN2 TTMHFRY Strong Biomarker [358]
EML4 TT92GY4 Strong Genetic Variation [195]
ENTPD1 TTYM8DJ Strong Altered Expression [359]
ERBB3 TTSINU2 Strong Biomarker [360]
F2R TTL935N Strong Genetic Variation [361]
FABP5 TTNT2S6 Strong Altered Expression [362]
FAS TT7LTUJ Strong Biomarker [363]
FASLG TTO7014 Strong Biomarker [363]
FGF10 TTNPEFX Strong Genetic Variation [364]
FGF7 TTFY134 Strong Genetic Variation [365]
FGFR4 TT1KX2S Strong Altered Expression [366]
GCG TT6Y4PN Strong Biomarker [223]
GDF15 TT4MXVG Strong Altered Expression [367]
GLRX TTRJCNG Strong Biomarker [368]
GM2A TTGOFW6 Strong Genetic Variation [195]
GRIK4 TTQV6BO Strong Genetic Variation [342]
GSTP1 TT40K12 Strong Genetic Variation [369]
GZMB TTKEPHX Strong Biomarker [370]
HDAC2 TTSHTOI Strong Altered Expression [371]
HPGDS TTCYE56 Strong Genetic Variation [372]
HTR2A TTJQOD7 Strong Biomarker [194]
IFNB1 TT4TZ8J Strong Biomarker [355]
IL17D TTC5LTG Strong Altered Expression [373]
IL17F TT2B6PS Strong Altered Expression [374]
IL18 TTRICUF Strong Biomarker [375]
IL22 TTLDX4N Strong Biomarker [376]
IL5 TTPREZD Strong Biomarker [377]
IL5RA TTXH9AD Strong Biomarker [378]
IRF3 TTYR7OH Strong Biomarker [379]
ITGA1 TTPERWV Strong Genetic Variation [195]
ITGAM TTB69FJ Strong Biomarker [380]
ITGB2 TTIJWR7 Strong Biomarker [380]
ITGB8 TTIF29E Strong Genetic Variation [195]
JAK3 TTT7PJU Strong Biomarker [381]
KCNK3 TTGR91N Strong Biomarker [382]
KCNMA1 TTE87WJ Strong Genetic Variation [383]
LTC4S TTW7OTG Strong Genetic Variation [384]
MAP3K19 TTRHJA3 Strong Biomarker [385]
MAPK14 TTQBR95 Strong Altered Expression [386]
MAS1 TTOISYB Strong Biomarker [387]
MCAM TTHRE05 Strong Altered Expression [388]
MMP12 TTXZ0KQ Strong Biomarker [247]
MMP14 TTJ4QE7 Strong Biomarker [389]
MMP7 TTMTWOS Strong Genetic Variation [390]
MPO TTVCZPI Strong Altered Expression [391]
MSR1 TT2TDH9 Strong Biomarker [392]
MUC1 TTBHFYQ Strong Biomarker [209]
MUC5AC TTEL90S Strong Altered Expression [340]
NELL1 TT7H4BF Strong Altered Expression [393]
NLRP1 TTQX29T Strong Genetic Variation [394]
NNT TTKIH76 Strong Genetic Variation [342]
NOS3 TTCM4B3 Strong Biomarker [395]
NPPB TTY63XT Strong Genetic Variation [396]
NRG1 TTEH395 Strong Genetic Variation [342]
NTF3 TTZHKV9 Strong Altered Expression [397]
PDE4A TTZ97H5 Strong Biomarker [398]
PIM3 TTCGOIN Strong Altered Expression [399]
PKD2L1 TTAHD89 Strong Genetic Variation [275]
PLA2G1B TT9V5JH Strong Biomarker [400]
PLAU TTGY7WI Strong Biomarker [401]
PLAUR TTNOSTX Strong Biomarker [402]
PRKCB TTYPXQF Strong Genetic Variation [342]
PRTN3 TT5MLC4 Strong Biomarker [403]
RARB TTISP28 Strong Genetic Variation [195]
RNPEP TTD74YX Strong Genetic Variation [342]
S100A9 TT0TMQG Strong Biomarker [404]
SLC1A5 TTF7WRM Strong Genetic Variation [405]
SLC1A7 TTK41DM Strong Genetic Variation [405]
SLC26A4 TT7X02I Strong Altered Expression [406]
SLC52A2 TT6TKEN Strong Genetic Variation [361]
SLC6A4 TT3ROYC Strong Genetic Variation [407]
SMAD6 TTON5JB Strong Altered Expression [408]
SORD TTLSRBZ Strong Altered Expression [409]
STAR TTEI40H Strong Altered Expression [410]
STAT6 TTWOE1T Strong Biomarker [411]
TESK2 TTRMD8U Strong Genetic Variation [195]
TGFB2 TTI0KH6 Strong Genetic Variation [412]
THRA TTTSEPU Strong Genetic Variation [195]
TLR2 TTY7ZHS Strong Biomarker [413]
TLR3 TTD24Y0 Strong Altered Expression [414]
TLR6 TTWRI8V Strong Genetic Variation [415]
TOP2B TT4NVEM Strong Genetic Variation [195]
TRPV4 TTKP2SU Strong Biomarker [416]
TSLP TTHMW3T Strong Altered Expression [417]
VIP TTGTWLF Strong Biomarker [418]
XRCC5 TTCB9KW Strong Genetic Variation [419]
APCS TTB7VAT Definitive Biomarker [420]
IL11 TTGUYTR Definitive Altered Expression [421]
IL25 TTVMO5W Definitive Altered Expression [417]
------------------------------------------------------------------------------------
⏷ Show the Full List of 315 DTT(s)
This Disease Is Related to 6 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC35F3 DTEHSG0 Limited Genetic Variation [178]
SLC11A1 DT650XW moderate Genetic Variation [422]
ANXA11 DTGQ2CF Strong Genetic Variation [423]
SLC25A20 DTQOUM4 Strong Biomarker [424]
SLC27A5 DT0TQS3 Strong Biomarker [341]
SLC30A10 DTYBI73 Strong Genetic Variation [195]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
This Disease Is Related to 9 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ACP3 DEDW5H6 Limited Biomarker [212]
CYP7B1 DE36TMY Limited Altered Expression [425]
DIO3 DET89OV Limited Altered Expression [182]
CES2 DETHCPD moderate Biomarker [426]
GSTO2 DEHMPZR moderate Genetic Variation [262]
MAT2B DEKF1OH moderate Biomarker [314]
NAT2 DER7TA0 moderate Genetic Variation [427]
CYP1A1 DE6OQ3W Strong Altered Expression [428]
LPO DEHX1DZ Strong Genetic Variation [342]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DME(s)
This Disease Is Related to 450 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACCS OTHIHI9D Limited Biomarker [429]
ACOT7 OT7C68YV Limited Genetic Variation [168]
ACTBL2 OTD6B81U Limited Genetic Variation [168]
ACTG2 OTRDWUO0 Limited Genetic Variation [168]
ADGRV1 OTLVXHHP Limited Genetic Variation [178]
AEBP1 OTBI1RZ6 Limited Biomarker [430]
AIM2 OT86QUI8 Limited Altered Expression [330]
ARHGAP12 OTTU94AU Limited Altered Expression [326]
ARHGAP42 OTIDSJMK Limited Genetic Variation [178]
ARHGEF38 OTA6K93F Limited Genetic Variation [431]
ASAP1 OT4DLRYY Limited Biomarker [212]
ASAP2 OTGEXULW Limited Biomarker [212]
AZIN2 OT8OB7CG Limited Biomarker [432]
BMF OT90NSLI Limited Biomarker [169]
BMP8A OT1997IN Limited Genetic Variation [178]
BMPR1A OTQOA4ZH Limited Altered Expression [433]
C1GALT1 OT2ZSZ6P Limited Genetic Variation [178]
CASZ1 OTWJ2OR8 Limited Genetic Variation [178]
CCL24 OT9LGHV0 Limited Altered Expression [332]
CD63 OT2UGZA9 Limited Altered Expression [434]
CD81 OTQFXNAZ Limited Biomarker [435]
CDH13 OTD2CYM5 Limited Genetic Variation [275]
COL4A3 OT6SB8X5 Limited Biomarker [436]
COL6A1 OTYKSCOB Limited Altered Expression [209]
COL6A2 OTQC6PPO Limited Altered Expression [209]
CRX OTH435SV Limited Biomarker [214]
CSMD1 OTIVDSC4 Limited Genetic Variation [302]
CUL4A OTTBV70J Limited Biomarker [437]
CXCL3 OTSL94KH Limited Altered Expression [438]
CYBA OT16N9ZO Limited Biomarker [439]
CYP2A7 OTRJ3P2Z Limited Genetic Variation [347]
DAB2IP OTF456VC Limited Altered Expression [440]
DCDC2 OTSUFH1H Limited Biomarker [441]
DHRS2 OTFHWIY8 Limited Biomarker [442]
DIO2 OTGPNSLH Limited Biomarker [443]
DLG2 OTQ3BD8U Limited Genetic Variation [444]
DNAH5 OTC21RUS Limited Genetic Variation [342]
DUSP6 OT4H6RKW Limited Biomarker [445]
FBL OTRODIE5 Limited Biomarker [446]
FBXO38 OTSZ3768 Limited Biomarker [447]
FHL5 OT6C00Z1 Limited Genetic Variation [168]
FUNDC1 OTA6IVKQ Limited Biomarker [448]
GADL1 OTJM4A0R Limited Biomarker [432]
GOT2 OT6XBWN0 Limited Altered Expression [449]
GPRC5A OTPOCWR7 Limited Altered Expression [450]
GSTCD OTIIINMT Limited Genetic Variation [431]
GTF2I OTUYL1TQ Limited Genetic Variation [178]
GZMA OT43R33L Limited Altered Expression [451]
HERC1 OT73FVYZ Limited Genetic Variation [178]
HMOX1 OTC1W6UX Limited Unknown [193]
HNRNPD OT5UO1FA Limited Altered Expression [452]
HSF2BP OTWKP0JC Limited Genetic Variation [178]
HSPA1A OTKGIE76 Limited Genetic Variation [190]
HYAL1 OT2SJN0X Limited Altered Expression [453]
HYKK OTBK1QPN Limited Genetic Variation [383]
IL10RA OTOX3D1D Limited Genetic Variation [454]
INTS12 OT0JKZ52 Limited Genetic Variation [195]
IRF7 OTC1A2PQ Limited Biomarker [355]
KCNK1 OTBXPTKX Limited Genetic Variation [275]
KLF15 OTGMQMVR Limited Biomarker [455]
LMNB1 OT100T3P Limited Altered Expression [181]
MAGT1 OTQSAV5C Limited Biomarker [169]
MGP OTZWU3FU Limited Biomarker [456]
MOK OTQK7M9V Limited Biomarker [457]
MRPS30 OTDXIAGG Limited Biomarker [212]
MTA2 OTCCYIQJ Limited Biomarker [458]
MTPAP OT6HQ02S Limited Biomarker [212]
NPNT OTFZAO1G Limited Genetic Variation [195]
NRL OT65MFKQ Limited Biomarker [459]
ORAI3 OTUP3OH3 Limited Altered Expression [460]
PAPOLA OTPHD65D Limited Biomarker [212]
PDAP1 OTJSWMOD Limited Biomarker [212]
PDZD2 OTPPVRGY Limited Genetic Variation [461]
PITX3 OTE2KT8P Limited Biomarker [462]
PLA2G15 OT6VJTPA Limited Biomarker [429]
POTEM OT7L2HGH Limited Genetic Variation [168]
PRKAG2 OTHTAM54 Limited Posttranslational Modification [463]
PSORS1C1 OT9HK436 Limited Genetic Variation [423]
RERE OT3G4GBZ Limited Genetic Variation [178]
RNF150 OTAMSBK5 Limited Genetic Variation [464]
ROBO2 OTFJ9FQW Limited Biomarker [465]
ROMO1 OTIEYVBW Limited Altered Expression [466]
RSPH6A OTJ96T2F Limited Genetic Variation [178]
RSRC1 OTFCJ4S0 Limited Genetic Variation [178]
S100A5 OTCGGL6K Limited Biomarker [209]
SAGE1 OT4H6FFA Limited Biomarker [467]
SAR1B OT0JZOMY Limited Biomarker [468]
SEMA6A OTDQ7QAW Limited Biomarker [175]
SH2B1 OTJZO2CI Limited Biomarker [469]
SPAM1 OTMPOB4E Limited Altered Expression [453]
SUMF1 OTALXO2A Limited Genetic Variation [188]
SYNPO2L OTA7RKXZ Limited Genetic Variation [178]
TAF1 OTDYS5G4 Limited Altered Expression [449]
TEAD4 OTJS0T2B Limited Biomarker [470]
TNNT1 OT8PBOAR Limited Biomarker [471]
TNRC6A OT493IOM Limited Genetic Variation [178]
TNS1 OTZ8S1PL Limited Genetic Variation [195]
DNAJC5 OTCZDXAL Disputed Biomarker [472]
DNER OT2GH2E5 Disputed Biomarker [473]
A2M OTFTX90K moderate Biomarker [474]
ABHD2 OTCRUOCS moderate Genetic Variation [475]
ADAMTS19 OTEG5Q2G moderate Biomarker [476]
ADIPOR2 OT2HDTL8 moderate Altered Expression [477]
AFAP1L2 OTJBI0VN moderate Biomarker [478]
AGPAT3 OTAUR5TG moderate Biomarker [301]
AKAP12 OTCVRDDX moderate Biomarker [479]
AKAP5 OTE2AGPC moderate Biomarker [479]
AMFR OTQRX7LC moderate Altered Expression [480]
AMOTL1 OT40G45S moderate Altered Expression [481]
APOM OTI3FQQC moderate Genetic Variation [482]
ARFGEF3 OTGQV0CU moderate Biomarker [318]
ATP6V1D OT4JDG0W moderate Genetic Variation [483]
BAMBI OTCEJ8W5 moderate Altered Expression [484]
BICD1 OT78IYPF moderate Genetic Variation [485]
BID OTOSHSHU moderate Biomarker [486]
BPIFA1 OTQFD2J5 moderate Altered Expression [487]
BPIFB1 OTOZYJMO moderate Altered Expression [487]
BTAF1 OTVVC0VL moderate Genetic Variation [306]
C4BPB OTJ70B0K moderate Biomarker [488]
CAMK1D OTU24HAU moderate Genetic Variation [489]
CCL13 OTNX0JD0 moderate Altered Expression [490]
CCL18 OT7JYSK9 moderate Altered Expression [491]
CCNL2 OT0NIKYM moderate Altered Expression [492]
CD1C OT4XINUJ moderate Altered Expression [238]
CD1D OT3ROU4J moderate Altered Expression [493]
CD5L OTPY4WQR moderate Altered Expression [494]
CD8A OTDWQJXK moderate Biomarker [495]
CDC6 OTX93FE7 moderate Biomarker [496]
CELSR1 OT7PS8O1 moderate Genetic Variation [497]
CENPJ OTZCQZN5 moderate Biomarker [498]
CFAP100 OTHHFM2Z moderate Altered Expression [499]
CFHR1 OT72R16T moderate Altered Expression [500]
CHERP OTJL4OB3 moderate Genetic Variation [501]
CIRBP OTXWTPBL moderate Altered Expression [502]
CLDN5 OTUX60YO moderate Altered Expression [503]
CLEC7A OTRTBH27 moderate Biomarker [504]
COMMD10 OT1ANQLQ moderate Biomarker [505]
COX5A OTP0961M moderate Biomarker [506]
CPOX OTIAY121 moderate Biomarker [506]
CRYGC OTYSTQWI moderate Biomarker [507]
CUL9 OTPUCLZT moderate Altered Expression [508]
CYFIP1 OTOBEH24 moderate Genetic Variation [501]
DBP OTE0W7LN moderate Genetic Variation [509]
DDX1 OT3U8FD0 moderate Biomarker [505]
DDX3Y OTKL1FNX moderate Biomarker [489]
DNAAF4 OTVDYBJE moderate Biomarker [510]
DSP OTB2MOP8 moderate Genetic Variation [195]
DUOX1 OTQ2AEW0 moderate Altered Expression [511]
DUOX2 OTU14HCN moderate Altered Expression [511]
DVL3 OTPRROHJ moderate Altered Expression [512]
EEFSEC OTJ4KKOO moderate Genetic Variation [195]
EIF1 OTB4GZ0V moderate Biomarker [304]
ELN OTFSO7PG moderate Biomarker [513]
ELP3 OTT5UKSZ moderate Biomarker [514]
ESAM OTF518AI moderate Biomarker [515]
FBLN1 OT5MHHOP moderate Biomarker [516]
FBLN5 OTLVNZ8U moderate Altered Expression [517]
FUT8 OTJJCVG1 moderate Altered Expression [518]
GPR65 OTCF5O4G moderate Genetic Variation [302]
GULP1 OT1WMVDH moderate Altered Expression [519]
HAS2 OTTD3PAL moderate Altered Expression [229]
HBE1 OTJPKMX4 moderate Biomarker [520]
HJURP OTWMV16B moderate Biomarker [308]
HOXA1 OTMSOJ7D moderate Genetic Variation [265]
HOXA10 OTB6GQ09 moderate Genetic Variation [265]
HOXA3 OTIX5XFB moderate Genetic Variation [265]
HOXA4 OTNVTQDT moderate Genetic Variation [265]
HOXA6 OTHJP8M2 moderate Genetic Variation [265]
HOXA9 OTKNK5H0 moderate Genetic Variation [265]
HSD17B6 OTSB55D2 moderate Altered Expression [313]
HSPA14 OTZCA5LK moderate Biomarker [521]
IFIH1 OTZA2AHA moderate Altered Expression [355]
IFIT1 OTXOQDSG moderate Altered Expression [522]
IFNL2 OT4BMJF7 moderate Biomarker [490]
IKBKE OT5VYOSM moderate Biomarker [307]
IKBKG OTNWJWSD moderate Biomarker [523]
IKZF1 OTCW1FKL moderate Genetic Variation [524]
IL17RA OTVVI8ER moderate Biomarker [525]
IL17RC OTEFOBSS moderate Biomarker [526]
IMPACT OTQ923OB moderate Biomarker [527]
INTS1 OT7TY1M1 moderate Biomarker [528]
KLF5 OT1ABI9N moderate Biomarker [529]
KLHL7 OT2OF1O8 moderate Biomarker [444]
KLK15 OT7BVG17 moderate Biomarker [530]
KRT18 OTVLQFIP moderate Biomarker [531]
MAGI2 OTXDDKZS moderate Altered Expression [532]
MAP1B OTVXW089 moderate Altered Expression [499]
MAPK13 OT0W9GE7 moderate Altered Expression [533]
MARCHF8 OTH7PNN2 moderate Genetic Variation [534]
MAVS OTTQ0J64 moderate Biomarker [285]
MCRS1 OT8K2X8P moderate Biomarker [308]
MFAP4 OT5W64QY moderate Altered Expression [517]
MLXIP OT30UNI7 moderate Genetic Variation [534]
MOCOS OT0TL3Q5 moderate Biomarker [535]
MSX1 OT5U41ZP moderate Biomarker [536]
MTCL1 OTY9ZKHE moderate Genetic Variation [195]
MUC2 OT3X4QVX moderate Biomarker [537]
MYCBP2 OTHODA1F moderate Biomarker [538]
MYLIP OTL0PFGV moderate Genetic Variation [534]
MYO1D OTP2RGPN moderate Genetic Variation [483]
MYO1E OTM9YSIZ moderate Biomarker [539]
NFKBIB OTY1ZJXH moderate Genetic Variation [540]
NLN OTFRITPU moderate Genetic Variation [541]
NR2C2 OTDZWVOJ moderate Altered Expression [542]
NT5DC1 OTNI9MFH moderate Genetic Variation [543]
NUP42 OTADT64E moderate Biomarker [444]
P2RX2 OT0LF34A moderate Biomarker [286]
P2RX5 OTLBR20R moderate Biomarker [286]
P2RX6 OT1FNTXA moderate Biomarker [286]
PACC1 OTKBS8CC moderate Biomarker [544]
PAGR1 OTXR5PQ8 moderate Genetic Variation [545]
PELI1 OTMLBCLC moderate Biomarker [546]
PHLPP2 OTXB1OUI moderate Altered Expression [547]
PI3 OT47MTC3 moderate Biomarker [548]
PID1 OT5YJ7FI moderate Biomarker [549]
PLA2G2D OTU604XM moderate Biomarker [550]
PLEKHM3 OT1YA9CS moderate Biomarker [551]
PPIC OTY5Q42N moderate Biomarker [552]
PPP1R15A OTYG179K moderate Altered Expression [553]
PPP4R4 OTKZDDIF moderate Biomarker [552]
PPRC1 OT6GB3WR moderate Biomarker [554]
PXDN OTFGGM9R moderate Biomarker [555]
RHOD OTALMEIN moderate Biomarker [556]
RHOQ OTUBTU57 moderate Biomarker [557]
RNASE3 OTVE2XD1 moderate Biomarker [558]
RNF5 OTDQGI37 moderate Altered Expression [480]
RPS3 OT0K3TMH moderate Biomarker [559]
RSAD2 OTCA9WCM moderate Altered Expression [267]
SARM1 OTEP4I5O moderate Biomarker [560]
SCAF1 OT16TM3N moderate Genetic Variation [501]
SDHAF3 OTD2JO6B moderate Biomarker [549]
SERPINA7 OTUYVTSU moderate Biomarker [561]
SFTPA2 OT6SFOMU moderate Genetic Variation [562]
SFTPC OTIZJD09 moderate Biomarker [563]
SLC16A4 OT1YXBKC moderate Altered Expression [215]
SMCP OTXKY794 moderate Biomarker [535]
SOCS5 OTN1ABYR moderate Biomarker [564]
SOX6 OTT0W0LE moderate Biomarker [271]
SP3 OTYDQZ1T moderate Genetic Variation [565]
SPX OTY3G4AR moderate Biomarker [566]
SRA1 OTYOGMTG moderate Genetic Variation [501]
SRF OTW18FQN moderate Biomarker [556]
TGFBR3 OTQOOUC4 moderate Biomarker [567]
TIMP4 OT8A68SW moderate Biomarker [568]
TNFRSF10C OTVHOL9B moderate Biomarker [569]
TNFSF8 OTDYGDJ3 moderate Altered Expression [570]
TNXB OTVBWAV5 moderate Genetic Variation [571]
TPR OTUBBA4W moderate Biomarker [314]
TRIM63 OTUSWA74 moderate Biomarker [572]
TSPYL4 OTHCX9RH moderate Genetic Variation [543]
ABLIM2 OT62KOXF Strong Genetic Variation [342]
ADAM19 OTH88TXU Strong Genetic Variation [195]
ADAMTSL3 OTMC2WFG Strong Genetic Variation [195]
ADGRG6 OTY2UBXO Strong Genetic Variation [195]
ADIPOR1 OT65ZFZN Strong Genetic Variation [573]
ADO OTRLGQ7V Strong Biomarker [574]
AHSA1 OTC7AFHT Strong Altered Expression [324]
AMZ1 OTDH9XM0 Strong Genetic Variation [195]
AQP5 OT77GBY8 Strong Altered Expression [575]
ARMC2 OTMCC01T Strong Genetic Variation [195]
ASTN2 OTF0W2FJ Strong Genetic Variation [195]
ATP2C2 OTGIHTYQ Strong Genetic Variation [423]
ATXN7L1 OT5EZO0M Strong Genetic Variation [383]
AZU1 OTHXU264 Strong Biomarker [576]
BCAS3 OTDVAX6B Strong Genetic Variation [577]
BEST1 OTWHE1ZC Strong Genetic Variation [578]
BNC2 OTU22H9Z Strong Genetic Variation [342]
BNIP3 OT4SO7J4 Strong Biomarker [579]
BTBD1 OTZTUI72 Strong Genetic Variation [195]
BTBD8 OT3A3RD7 Strong Genetic Variation [580]
BTBD9 OTWQ6GA3 Strong Genetic Variation [342]
BTC OTW4B2O0 Strong Genetic Variation [195]
C1orf185 OT32C5NW Strong Genetic Variation [342]
C4A OTXMOYXU Strong Altered Expression [328]
CAP1 OTYM8A2N Strong Biomarker [581]
CASP12 OTY2W6FG Strong Therapeutic [582]
CCDC69 OT43MI0R Strong Genetic Variation [195]
CCDC91 OTLZNXDL Strong Genetic Variation [195]
CCL28 OTY6XNQ7 Strong Genetic Variation [342]
CD207 OTI9RUDN Strong Biomarker [583]
CDYL OTCUK5KZ Strong Genetic Variation [250]
CEP70 OTMY5KAE Strong Genetic Variation [383]
CFAP221 OTUVNCVZ Strong Genetic Variation [584]
CFAP97 OT0RSQO4 Strong Biomarker [585]
CFDP1 OTXY7J96 Strong Genetic Variation [195]
CH25H OT9S2BSW Strong Altered Expression [425]
CHI3L1 OT2Z7VJH Strong Altered Expression [586]
CIB2 OT9ZJX1I Strong Biomarker [587]
CIP2A OTVS2GXA Strong Biomarker [588]
CNTN4 OTULXVE0 Strong Genetic Variation [589]
CRACR2B OT8L843R Strong Genetic Variation [584]
CSTA OT1K68KE Strong Altered Expression [590]
CXCL5 OTZOUPCA Strong Biomarker [591]
CYFIP2 OTCAY35T Strong Genetic Variation [592]
CYS1 OTUXN7CO Strong Genetic Variation [584]
DDIT3 OTI8YKKE Strong Therapeutic [582]
DEFA1 OT5N1B9B Strong Biomarker [593]
DENND2D OTXEFJWM Strong Genetic Variation [195]
DMWD OT0CBZ6F Strong Genetic Variation [195]
DOCK1 OTCFV3ON Strong Biomarker [589]
DPP6 OTWW3H0K Strong Genetic Variation [342]
EFCAB5 OTKVCIP6 Strong Genetic Variation [195]
FAIM2 OT6QINVO Strong Biomarker [363]
FAM227B OTDZYIIY Strong Genetic Variation [594]
FBXL7 OTNUK1DJ Strong Genetic Variation [342]
FBXO32 OTUE978R Strong Biomarker [595]
FGD6 OTI0T62C Strong Genetic Variation [195]
FGL1 OTT0QHQ1 Strong Genetic Variation [275]
GAB2 OTBFN705 Strong Genetic Variation [178]
GABPA OT9YB2SA Strong Altered Expression [596]
GALNT13 OT650121 Strong Genetic Variation [275]
GC OTWS63BY Strong Genetic Variation [597]
GDAP1 OTQE1O25 Strong Genetic Variation [342]
GDF11 OTOSNMND Strong Biomarker [598]
GLIS3 OTBC960E Strong Genetic Variation [195]
GPR15 OTK8674M Strong Altered Expression [599]
GRAP2 OTS5NIZ3 Strong Altered Expression [324]
GSTM2 OTG4WT05 Strong Genetic Variation [600]
GTF2H1 OTCRXC6B Strong Altered Expression [601]
GYPA OTABU4YV Strong Genetic Variation [602]
GYPB OTESHUIX Strong Genetic Variation [602]
GYPE OTBHAG6A Strong Genetic Variation [602]
HDLBP OTKDEEYX Strong Biomarker [576]
HEBP1 OTR9MPDX Strong Biomarker [576]
HLA-DPA1 OT7OG7Y2 Strong Biomarker [603]
HLA-DPB1 OTW8JHU2 Strong Biomarker [603]
HLA-DRB3 OT5PM9N7 Strong Biomarker [603]
HOOK2 OTPO4NQV Strong Genetic Variation [275]
HSBP1 OTHZRMOF Strong Genetic Variation [275]
HSPA4 OT5HR0AR Strong Genetic Variation [195]
IL17C OTKXIVNQ Strong Biomarker [604]
IL26 OT2WYCW4 Strong Biomarker [605]
IL27 OTIS3OF8 Strong Altered Expression [373]
INSRR OT3F75WA Strong Biomarker [606]
ITPK1 OTP4PGL6 Strong Genetic Variation [195]
KCNG4 OT7AOD0Y Strong Genetic Variation [275]
KL OTD4VWU6 Strong Biomarker [607]
KLF2 OTIP1UFX Strong Altered Expression [608]
KLHL32 OTTH5A33 Strong Genetic Variation [342]
LAMA1 OTQZMP86 Strong Biomarker [609]
LAYN OT9A9Q1X Strong Biomarker [610]
LRMDA OTIPNKTU Strong Genetic Variation [195]
LTBP4 OTC8WL2V Strong Genetic Variation [611]
LYSMD4 OTWSULBF Strong Genetic Variation [342]
MAML3 OTZFV53Z Strong Genetic Variation [612]
MARCO OT0NW2Q0 Strong Genetic Variation [501]
MEF2D OT7CEIG0 Strong Altered Expression [613]
MFAP2 OTMHVBTV Strong Genetic Variation [195]
MFHAS1 OTS922CJ Strong Genetic Variation [195]
MICAL3 OTD229X7 Strong Genetic Variation [195]
MKS1 OT83W5PB Strong Genetic Variation [342]
MMP28 OTHQZXM1 Strong Biomarker [614]
MMRN1 OT7ZNYHT Strong Altered Expression [615]
MMS22L OTJI0HM9 Strong Genetic Variation [342]
MTHFD1 OTMKHVWC Strong Genetic Variation [323]
MUC5B OTPW6K5C Strong Biomarker [616]
MUC6 OTPVL723 Strong Biomarker [617]
MYDGF OT9HRPL6 Strong Altered Expression [417]
NFATC3 OTYOORME Strong Biomarker [618]
NOL4L OT14W6UW Strong Genetic Variation [431]
NTM OTHF0UQU Strong Biomarker [619]
NUP62 OTMN63DH Strong Altered Expression [601]
NWD1 OT4JMFPH Strong Genetic Variation [275]
OMP OT7JH0DY Strong Altered Expression [620]
OR6F1 OTFNOC4Q Strong Genetic Variation [275]
ORMDL3 OTAB7MZF Strong Genetic Variation [621]
PARP9 OT7K4494 Strong Biomarker [341]
PCBP2 OTXCN9CG Strong Altered Expression [622]
PCDH15 OTU9C2EH Strong Genetic Variation [577]
PCDH9 OTX3BFV4 Strong Genetic Variation [383]
PCM1 OTFM133C Strong Genetic Variation [275]
PDSS2 OTEOQBMX Strong Genetic Variation [577]
PGAM5 OT6Q5M0C Strong Altered Expression [623]
PIGR OT6GLSUL Strong Altered Expression [624]
PINK1 OT50NR57 Strong Biomarker [625]
PIR OT8ALXHU Strong Biomarker [626]
PITPNA OTTWC00K Strong Genetic Variation [275]
PLA2G10 OTRZ2L5A Strong Genetic Variation [627]
PLAAT4 OTI66SAJ Strong Altered Expression [355]
PLB1 OTZ6TTYV Strong Genetic Variation [178]
PLCE1 OTJISZOX Strong Genetic Variation [250]
PLXNA4 OT5XKB3Q Strong Genetic Variation [275]
PNPT1 OTBR2Q0F Strong Altered Expression [628]
POFUT1 OTOBJZIT Strong Genetic Variation [431]
POLDIP2 OT8SZSJ6 Strong Altered Expression [324]
PTPA OTRGFOI7 Strong Altered Expression [341]
PTX3 OTPXHRKU Strong Biomarker [462]
RAB4B OTTT4DY3 Strong Genetic Variation [431]
RBM8A OT5SR6G0 Strong Biomarker [629]
RBMS3 OTFSC9MR Strong Genetic Variation [195]
RNASEH2A OT8G3G7K Strong Genetic Variation [275]
RNF19A OTKWCV80 Strong Altered Expression [324]
RNF220 OT2FIEXO Strong Genetic Variation [195]
ROBO3 OTPVG40S Strong Altered Expression [355]
ROM1 OTE7H0YV Strong Biomarker [630]
RREB1 OT62460U Strong Genetic Variation [195]
SARDH OTQ49Q27 Strong Altered Expression [409]
SCFD2 OTYM55ET Strong Genetic Variation [250]
SCLT1 OT2ZSSP4 Strong Genetic Variation [412]
SDC4 OTKUVUGZ Strong Altered Expression [631]
SDHB OTRE1M1T Strong Altered Expression [409]
SDS OT5WTJ2M Strong Altered Expression [409]
SERPINA3 OT9BP2S0 Strong Genetic Variation [168]
SESN2 OT889IXY Strong Altered Expression [632]
SFRP5 OTLCVVSH Strong Biomarker [633]
SFTPA1 OT87XL1U Strong Genetic Variation [562]
SGCD OTRBL3NQ Strong Genetic Variation [275]
SGF29 OTTE5GOJ Strong Genetic Variation [431]
SIGLEC14 OT2JGGXD Strong Genetic Variation [339]
SIGLEC8 OTQ5TRRV Strong Genetic Variation [339]
SIGLEC9 OTZC7SIM Strong Genetic Variation [634]
SLBP OTVYYQRT Strong Biomarker [576]
SLMAP OTHW3DVC Strong Genetic Variation [195]
SLPI OTUNFUU8 Strong Altered Expression [624]
SMAD2 OTC6VB4K Strong Biomarker [635]
SMAD4 OTWQWCKG Strong Altered Expression [636]
SMPD3 OTHQBETH Strong Biomarker [637]
SNTG2 OTD8HJCD Strong Genetic Variation [342]
SOD3 OTIOZQAB Strong Altered Expression [638]
SPAG16 OTIFUPYD Strong Genetic Variation [342]
SPINT1 OT1CLR5L Strong Genetic Variation [639]
SPPL2C OTUTY2ED Strong Genetic Variation [195]
STAM2 OT9OBWPH Strong Biomarker [576]
STAT4 OTAK3VFR Strong Genetic Variation [411]
STN1 OT8UWRA3 Strong Genetic Variation [195]
STPG4 OT5K4UFL Strong Altered Expression [613]
SYCP2L OT926TNQ Strong Genetic Variation [275]
SYN3 OTSGYNA5 Strong Genetic Variation [195]
TAFA2 OTU6WP6J Strong Genetic Variation [342]
TBX4 OTW58FG4 Strong Genetic Variation [342]
TET2 OTKKT03T Strong Genetic Variation [195]
TFAM OTXXV5V7 Strong Posttranslational Modification [640]
THSD4 OTXDBMDC Strong Genetic Variation [195]
TIMP2 OT8S1RRP Strong Altered Expression [641]
TM9SF4 OT85D4H9 Strong Genetic Variation [431]
TMEM254 OTGDPU8S Strong Genetic Variation [423]
TNPO1 OT7W2CM8 Strong Genetic Variation [195]
TOX2 OT7RZRVK Strong Genetic Variation [342]
TPSG1 OTDESHKT Strong Biomarker [642]
TSHZ3 OTAN7RY5 Strong Genetic Variation [342]
TSPAN14 OT29167O Strong Genetic Variation [195]
CCL1 OT23NON8 Definitive Altered Expression [421]
CXCL14 OTM189TA Definitive Altered Expression [643]
FAM13A OTZ6GN0Q Definitive Genetic Variation [195]
FOXO3 OTHXQG4P Definitive Altered Expression [644]
HHIP OT77RQYS Definitive Genetic Variation [645]
MSC OTBRPZL5 Definitive Biomarker [646]
RIT1 OTVNOGOH Definitive Genetic Variation [647]
SH2D1A OTLU49I5 Definitive Biomarker [420]
TIMP1 OTOXC51H Definitive Biomarker [648]
------------------------------------------------------------------------------------
⏷ Show the Full List of 450 DOT(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7449).
2 Improving oxygenation during bronchopulmonary lavage using nitric oxide inhalation and almitrine infusion. Anesth Analg. 1999 Aug;89(2):302-4.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7479).
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
6 Clinical pipeline report, company report or official report of Novartis.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7455).
8 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7543).
11 Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5484).
13 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6962).
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 559).
16 FDA Approves Symbicort for Chronic Obstructive Pulmonary Disease
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 413).
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 367).
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028430)
22 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
23 ClinicalTrials.gov (NCT05878769) A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7730).
25 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
26 ClinicalTrials.gov (NCT04701983) Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
27 ClinicalTrials.gov (NCT00971035) A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
28 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
29 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029986)
30 ClinicalTrials.gov (NCT02343458) Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD. U.S. National Institutes of Health.
31 ClinicalTrials.gov (NCT02554786) A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma.
32 Clinical pipeline report, company report or official report of Novartis.
33 ClinicalTrials.gov (NCT02276222) A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD. U.S. National Institutes of Health.
34 ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
35 Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016274)
37 ClinicalTrials.gov (NCT02324972) Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT02109406) Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD. U.S. National Institutes of Health.
39 ClinicalTrials.gov (NCT01215279) AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) in AstraZeneca.
40 ClinicalTrials.gov (NCT01708057) A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
41 ClinicalTrials.gov (NCT00939211) The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7680).
43 ClinicalTrials.gov (NCT02479412) A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma.
44 ClinicalTrials.gov (NCT02238483) A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy. U.S. National Institutes of Health.
45 ClinicalTrials.gov (NCT03645434) A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD. U.S.National Institutes of Health.
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7826).
47 ClinicalTrials.gov (NCT00703391) A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
48 ClinicalTrials.gov (NCT01332097) Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation. U.S. National Institutes of Health.
49 ClinicalTrials.gov (NCT00648245) Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD. U.S. National Institutes of Health.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7582).
51 ClinicalTrials.gov (NCT04882124) A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
52 ClinicalTrials.gov (NCT03414541) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Chronic Obstructive Pulmonary Disease Patients. U.S.National Institutes of Health.
53 ClinicalTrials.gov (NCT01426009) Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101 in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study. U.S. National Institutes of Health.
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8500).
55 ClinicalTrials.gov (NCT01154101) Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis. U.S. National Institutes of Health.
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024247)
57 ClinicalTrials.gov (NCT03118765) A Dose Ranging, Parallel Group, Active (Spiriva? Respimat?) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
58 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
59 Clinical pipeline report, company report or official report of Amarillo Biosciences.
60 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6563).
61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 841).
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026746)
63 A novel phosphodiesterase 4 inhibitor template. Expert Opinion on Therapeutic Patents,2003, 13(6), 929-933.
64 ClinicalTrials.gov (NCT01461915) Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane. U.S. National Institutes ofHealth.
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022098)
66 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8179).
67 ClinicalTrials.gov (NCT01033487) A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495)
69 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7818).
70 ClinicalTrials.gov (NCT01006161) Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1). U.S. National Institutes of Health.
71 ClinicalTrials.gov (NCT01068613) Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
72 ClinicalTrials.gov (NCT01972776) A Safety, Tolerability and Efficacy Study in COPD Patients With QBM076.. U.S. National Institutes of Health.
73 ClinicalTrials.gov (NCT04268823) A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
74 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8499).
75 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8497).
76 ClinicalTrials.gov (NCT04540042) A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 in Subjects With Chronic Obstructive Pulmonary Disease (Part 2). U.S.National Institutes of Health.
77 ClinicalTrials.gov (NCT00874497) Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema. U.S. National Institutes of Health.
78 Clinical pipeline report, company report or official report of Theravance.
79 ClinicalTrials.gov (NCT00150397) A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics. U.S. National Institutes of Health.
80 ClinicalTrials.gov (NCT00483743) Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients. U.S. National Institutes of Health.
81 ClinicalTrials.gov (NCT02382510) Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics. U.S. National Institutes of Health.
82 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8420).
83 ClinicalTrials.gov (NCT00464932) Vasoactive Intestinal Peptide in COPD. U.S. National Institutes of Health.
84 ClinicalTrials.gov (NCT02272634) A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD. U.S.National Institutes of Health.
85 ClinicalTrials.gov (NCT05643729) A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of ZofinTM for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
86 ClinicalTrials.gov (NCT00860353) Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551. U.S. National Institutes of Health.
87 ClinicalTrials.gov (NCT00984477) Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects. U.S. National Institutes of Health.
88 ClinicalTrials.gov (NCT01166698) Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects. U.S. National Institutes of Health.
89 ClinicalTrials.gov (NCT01889160) Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels. U.S. National Institutes of Health.
90 ClinicalTrials.gov (NCT04656275) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Oral Doses of BI 1323495 Bid Versus Placebo in Patients With Non-cystic Fibrosis Bronchiectasis (Randomised, Double-blind, Placebo-controlled, Parallel Group Trial). U.S.National Institutes of Health.
91 ClinicalTrials.gov (NCT01348165) Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers. U.S. National Institutes of Health.
92 ClinicalTrials.gov (NCT03235726) A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Inhalation Powder in Healthy Participants and Participants With Moderate Chronic Obstructive Pulmonary Disease (COPD) Including Evaluation of Environmental and Healthy By-stander Exposure Levels During Dosing. U.S.National Institutes of Health.
93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028438)
94 Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301.
95 ClinicalTrials.gov (NCT05677347) A Randomized, Double-blind, Placebo Controlled, Single and Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
96 ClinicalTrials.gov (NCT01322594) A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
97 ClinicalTrials.gov (NCT01544361) A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers. U.S. National Institutes of Health.
98 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
99 ClinicalTrials.gov (NCT01921712) A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients. U.S. National Institutes of Health.
100 ClinicalTrials.gov (NCT04759807) A Phase 1b 3-way Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Once Daily Doses of PUR1800 in Adult Patients With Stable Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
101 ClinicalTrials.gov (NCT01197287) Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
102 ClinicalTrials.gov (NCT01009424) A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
103 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013990)
104 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
105 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
106 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000036)
107 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000603)
108 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7407).
109 Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17.
110 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031497)
111 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7844).
112 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025769)
113 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001581)
114 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003087)
115 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003784)
116 Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev. 2009 Nov;29(6):867-902.
117 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015988)
118 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003918)
119 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017535)
120 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007577)
121 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025582)
122 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003718)
123 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003767)
124 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021444)
125 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015539)
126 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009741)
127 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019126)
128 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009803)
129 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703)
130 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017126)
131 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017125)
132 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7728).
133 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029299)
134 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029210)
135 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027710)
136 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012873)
137 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023203)
138 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001252)
139 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014165)
140 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010874)
141 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009537)
142 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024139)
143 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 781).
144 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015052)
145 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263)
146 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019127)
147 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)
148 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022142)
149 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008813)
150 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020194)
151 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014569)
152 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000057)
153 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
154 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
155 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
156 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
157 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031503)
158 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).
159 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
160 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17).
161 Clinical pipeline report, company report or official report of GlaxoSmithKline.
162 ClinicalTrials.gov (NCT00911651) Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. U.S. National Institutes of Health.
163 Duaklir Genuair approved in the European Union for chronic obstructive pulmonary disease
164 Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015 Aug 13:1-11.
165 ClinicalTrials.gov (NCT01316900) 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease. U.S. National Institutes of Health.
166 Clinical pipeline report, company report or official report of GlaxoSmithKline.
167 Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.Clin Drug Investig. 2018 Jul;38(7):611-620. doi: 10.1007/s40261-018-0646-0.
168 COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines?.Chron Respir Dis. 2019 Jan-Dec;16:1479973119867949. doi: 10.1177/1479973119867949.
169 Risk of COPD due to indoor air pollution from biomass cooking fuel: a systematic review and meta-analysis.Int J Environ Health Res. 2020 Feb;30(1):75-88. doi: 10.1080/09603123.2019.1575951. Epub 2019 Feb 13.
170 Increased expression of human calcium-activated chloride channel 1 is correlated with mucus overproduction in the airways of Chinese patients with chronic obstructive pulmonary disease.Chin Med J (Engl). 2007 Jun 20;120(12):1051-7.
171 [Reduced expression of the sarcoplasmic calcium pump SERCA2 in skeletal muscle from patients with chronic obstructive pulmonary disease and low body weight].Arch Bronconeumol. 2007 Jan;43(1):4-8. doi: 10.1016/s1579-2129(07)60013-5.
172 Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients.Int J Chron Obstruct Pulmon Dis. 2019 Oct 31;14:2433-2440. doi: 10.2147/COPD.S221466. eCollection 2019.
173 Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization.J Clin Lab Anal. 2019 Jul;33(6):e22908. doi: 10.1002/jcla.22908. Epub 2019 May 20.
174 CARM1 regulates senescence during airway epithelial cell injury in COPD pathogenesis.Am J Physiol Lung Cell Mol Physiol. 2019 Nov 1;317(5):L602-L614. doi: 10.1152/ajplung.00441.2018. Epub 2019 Aug 28.
175 MiR-34c-5p plays a protective role in chronic obstructive pulmonary disease via targeting CCL22.Exp Lung Res. 2019 Feb-Mar;45(1-2):1-12. doi: 10.1080/01902148.2018.1563925. Epub 2019 Apr 29.
176 PET-based Imaging of Chemokine Receptor 2 in Experimental and Disease-related Lung Inflammation.Radiology. 2017 Jun;283(3):758-768. doi: 10.1148/radiol.2016161409. Epub 2017 Jan 3.
177 CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity.Am J Pathol. 2007 Sep;171(3):767-76. doi: 10.2353/ajpath.2007.061177. Epub 2007 Jul 19.
178 Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis.Respir Res. 2019 Apr 2;20(1):64. doi: 10.1186/s12931-019-1036-8.
179 High expression of CDH3 predicts a good prognosis for colon adenocarcinoma patients.Exp Ther Med. 2019 Jul;18(1):841-847. doi: 10.3892/etm.2019.7638. Epub 2019 Jun 3.
180 Rhinovirus-induces progression of lung disease in a mouse model of COPD via IL-33/ST2 signaling axis.Clin Sci (Lond). 2019 Apr 29;133(8):983-996. doi: 10.1042/CS20181088. Print 2019 Apr 30.
181 Involvement of Lamin B1 Reduction in Accelerated Cellular Senescence during Chronic Obstructive Pulmonary Disease Pathogenesis.J Immunol. 2019 Mar 1;202(5):1428-1440. doi: 10.4049/jimmunol.1801293. Epub 2019 Jan 28.
182 Assessment of serum levels of DIO1 and DIO3 in patients diagnosed with COPD.Adv Med Sci. 2019 Sep;64(2):344-348. doi: 10.1016/j.advms.2019.04.001. Epub 2019 Apr 22.
183 Neutrophil extracellular traps promote lipopolysaccharide-induced airway inflammation and mucus hypersecretion in mice.Oncotarget. 2018 Jan 8;9(17):13276-13286. doi: 10.18632/oncotarget.24022. eCollection 2018 Mar 2.
184 Overexpression Of hsa-miR-664a-3p Is Associated With Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Via Targeting FHL1.Int J Chron Obstruct Pulmon Dis. 2019 Oct 9;14:2319-2329. doi: 10.2147/COPD.S224763. eCollection 2019.
185 FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting.Int J Mol Sci. 2019 Apr 24;20(8):2024. doi: 10.3390/ijms20082024.
186 Defective formyl peptide receptor 2/3 and annexin A1 expressions associated with M2a polarization of blood immune cells in patients with chronic obstructive pulmonary disease.J Transl Med. 2018 Mar 15;16(1):69. doi: 10.1186/s12967-018-1435-5.
187 Genome-wide association analysis of body mass in chronic obstructive pulmonary disease.Am J Respir Cell Mol Biol. 2011 Aug;45(2):304-10. doi: 10.1165/rcmb.2010-0294OC. Epub 2010 Oct 29.
188 Expression, activity and localization of lysosomal sulfatases in Chronic Obstructive Pulmonary Disease.Sci Rep. 2019 Feb 13;9(1):1991. doi: 10.1038/s41598-018-37958-w.
189 Altered DNA methylation is associated with aberrant gene expression in parenchymal but not airway fibroblasts isolated from individuals with COPD.Clin Epigenetics. 2018 Mar 5;10:32. doi: 10.1186/s13148-018-0464-5. eCollection 2018.
190 Associations of the NRF2/KEAP1 pathway and antioxidant defense gene polymorphisms with chronic obstructive pulmonary disease.Gene. 2019 Apr 15;692:102-112. doi: 10.1016/j.gene.2018.12.061. Epub 2019 Jan 12.
191 Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients.Respir Res. 2007 Jul 6;8(1):48. doi: 10.1186/1465-9921-8-48.
192 Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies.Lab Invest. 2019 Feb;99(2):150-157. doi: 10.1038/s41374-018-0146-0. Epub 2018 Nov 19.
193 Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000 Jan;66(1):187-95. doi: 10.1086/302729.
194 Serotonin receptors 5-HTR2A and 5-HTR2B are involved in cigarette smoke-induced airway inflammation, mucus hypersecretion and airway remodeling in mice.Int Immunopharmacol. 2020 Apr;81:106036. doi: 10.1016/j.intimp.2019.106036. Epub 2019 Nov 29.
195 Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.Nat Genet. 2019 Mar;51(3):494-505. doi: 10.1038/s41588-018-0342-2. Epub 2019 Feb 25.
196 IFN3/4 locus polymorphisms and IFN3 circulating levels are associated with COPD severity and outcomes.BMC Pulm Med. 2018 Mar 21;18(1):51. doi: 10.1186/s12890-018-0616-6.
197 Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15R.Am J Respir Crit Care Med. 2018 Nov 1;198(9):1140-1150. doi: 10.1164/rccm.201712-2513OC.
198 Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection.J Infect Chemother. 2018 Oct;24(10):822-827. doi: 10.1016/j.jiac.2018.06.014. Epub 2018 Jul 25.
199 IL-33 induces production of autoantibody against autologous respiratory epithelial cells: a potential mechanism for the pathogenesis of COPD.Immunology. 2019 Jun;157(2):137-150. doi: 10.1111/imm.13054. Epub 2019 Mar 27.
200 Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease.J Clin Invest. 2018 Jun 1;128(6):2406-2418. doi: 10.1172/JCI98224. Epub 2018 Apr 30.
201 Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis.Integr Cancer Ther. 2019 Jan-Dec;18:1534735419864434. doi: 10.1177/1534735419864434.
202 Tobacco-Derived Lipopolysaccharide, Not Microbial Translocation, as a Potential Contributor to the Pathogenesis of Rheumatoid Arthritis.Mediators Inflamm. 2019 Nov 3;2019:4693870. doi: 10.1155/2019/4693870. eCollection 2019.
203 Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation.Drug Des Devel Ther. 2019 Sep 4;13:3105-3116. doi: 10.2147/DDDT.S215433. eCollection 2019.
204 Functional polymorphisms in NFB1/IB predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese.Hum Genet. 2013 Apr;132(4):451-60. doi: 10.1007/s00439-013-1264-9. Epub 2013 Jan 16.
205 Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.
206 miR-4709 overexpression facilitates cancer proliferation and invasion via downregulating NR3C2 and is an unfavorable prognosis factor in colon adenocarcinoma.J Biochem Mol Toxicol. 2019 Dec;33(12):e22411. doi: 10.1002/jbt.22411. Epub 2019 Oct 17.
207 The association of neuron-derived orphan receptor 1 with pulmonary vascular remodeling in COPD patients.Int J Chron Obstruct Pulmon Dis. 2018 Apr 13;13:1177-1186. doi: 10.2147/COPD.S151820. eCollection 2018.
208 Long non-coding RNA ZEB1-AS1 promotes colon adenocarcinoma malignant progression via miR-455-3p/PAK2 axis.Cell Prolif. 2020 Jan;53(1):e12723. doi: 10.1111/cpr.12723. Epub 2019 Dec 12.
209 Toxicological effects of ambient fine (PM(2.5-0.18)) and ultrafine (PM(0.18)) particles in healthy and diseased 3D organo-typic mucocilary-phenotype models.Environ Res. 2019 Sep;176:108538. doi: 10.1016/j.envres.2019.108538. Epub 2019 Jun 15.
210 Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease.Respirology. 2020 Jan;25(1):53-63. doi: 10.1111/resp.13722. Epub 2019 Oct 30.
211 Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.Am J Respir Cell Mol Biol. 2019 Apr;60(4):445-453. doi: 10.1165/rcmb.2018-0065OC.
212 The evaluation of cardiac functions according to chronic obstructive pulmonary disease groups.Aging Male. 2020 Jun;23(2):106-111. doi: 10.1080/13685538.2019.1606191. Epub 2019 Apr 30.
213 Gene silencing of receptor-interacting protein 2 protects against cigarette smoke-induced acute lung injury.Pharmacol Res. 2019 Jan;139:560-568. doi: 10.1016/j.phrs.2018.10.016. Epub 2018 Oct 28.
214 The Qigong Wuqinxi for chronic obstructive pulmonary disease: Protocol for a systematic review and meta-analysis.Medicine (Baltimore). 2019 Jul;98(30):e16633. doi: 10.1097/MD.0000000000016633.
215 Altered metabolic and transporter characteristics of vastus lateralis in chronic obstructive pulmonary disease.J Appl Physiol (1985). 2008 Sep;105(3):879-86. doi: 10.1152/japplphysiol.90458.2008. Epub 2008 Jul 17.
216 Characterization of an immortalized human small airway basal stem/progenitor cell line with airway region-specific differentiation capacity.Respir Res. 2019 Aug 23;20(1):196. doi: 10.1186/s12931-019-1140-9.
217 Sp1 contributes to overexpression of stanniocalcin 2 through regulation of promoter activity in colon adenocarcinoma.World J Gastroenterol. 2019 Jun 14;25(22):2776-2787. doi: 10.3748/wjg.v25.i22.2776.
218 Increased neurokinin-2 receptor expression in alveolar macrophages of smokers with COPD.Histopathology. 2007 Jul;51(1):128-31. doi: 10.1111/j.1365-2559.2007.02716.x. Epub 2007 May 26.
219 TREM2-Ligand Interactions in Health and Disease.J Mol Biol. 2017 Jun 2;429(11):1607-1629. doi: 10.1016/j.jmb.2017.04.004. Epub 2017 Apr 19.
220 TRPC channels mediated calcium entry is required for proliferation of human airway smooth muscle cells induced by nicotine-nAChR.Biochimie. 2019 Mar;158:139-148. doi: 10.1016/j.biochi.2018.12.004. Epub 2018 Dec 11.
221 Reduced transient receptor potential vanilloid 2 expression in alveolar macrophages causes COPD in mice through impaired phagocytic activity.BMC Pulm Med. 2019 Mar 26;19(1):70. doi: 10.1186/s12890-019-0821-y.
222 Prognostic significance of high YY1AP1 and PCNA expression in colon adenocarcinoma.Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):173-180. doi: 10.1016/j.bbrc.2017.10.060. Epub 2017 Oct 15.
223 Endothelial Progenitor Cells as Pathogenetic and Diagnostic Factors, and Potential Targets for GLP-1 in Combination with Metabolic Syndrome and Chronic Obstructive Pulmonary Disease.Int J Mol Sci. 2019 Mar 4;20(5):1105. doi: 10.3390/ijms20051105.
224 HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-B p65 transcriptional activity.Biochem Pharmacol. 2016 May 15;108:58-74. doi: 10.1016/j.bcp.2016.03.010. Epub 2016 Mar 16.
225 Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.Mucosal Immunol. 2016 Sep;9(5):1317-29. doi: 10.1038/mi.2015.138. Epub 2016 Jan 27.
226 Fat-free mass depletion in patients with COPD in Brazil: development of a new cutoff point and its relation with mortality and extrapulmonary manifestations.Eur J Clin Nutr. 2017 Nov;71(11):1285-1290. doi: 10.1038/ejcn.2017.105. Epub 2017 Jul 19.
227 A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD.Am J Respir Crit Care Med. 2018 Jun 4;198(12):1500-18. doi: 10.1164/rccm.201711-2300OC. Online ahead of print.
228 CHRNA3/5, IREB2, and ADCY2 are associated with severe chronic obstructive pulmonary disease in Poland.Am J Respir Cell Mol Biol. 2012 Aug;47(2):203-8. doi: 10.1165/rcmb.2012-0011OC. Epub 2012 Mar 29.
229 Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease.Am J Respir Cell Mol Biol. 2013 Dec;49(6):1038-47. doi: 10.1165/rcmb.2013-0089OC.
230 Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different 1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study.Front Pharmacol. 2018 Oct 25;9:1212. doi: 10.3389/fphar.2018.01212. eCollection 2018.
231 Correlation of serum vascular adhesion protein-1 with airflow limitation and quality of life in stable chronic obstructive pulmonary disease.Respir Med. 2017 Nov;132:149-153. doi: 10.1016/j.rmed.2017.10.011. Epub 2017 Oct 16.
232 Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease.J Mol Med (Berl). 2018 Dec;96(12):1375-1385. doi: 10.1007/s00109-018-1708-8. Epub 2018 Oct 23.
233 Activating transcription factor 3 represses cigarette smoke-induced IL6 and IL8 expression via suppressing NF-B activation.Toxicol Lett. 2017 Mar 15;270:17-24. doi: 10.1016/j.toxlet.2017.02.002. Epub 2017 Feb 6.
234 A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment.Am J Respir Crit Care Med. 2013 May 1;187(9):933-42. doi: 10.1164/rccm.201208-1449OC.
235 A Functional Variant rs6435156C > T in BMPR2 is Associated With Increased Risk of Chronic Obstructive Pulmonary Disease (COPD) in Southern Chinese Population.EBioMedicine. 2016 Feb 5;5:167-74. doi: 10.1016/j.ebiom.2016.02.004. eCollection 2016 Mar.
236 Analyze and Identify Peiminine Target EGFR Improve Lung Function and Alleviate Pulmonary Fibrosis to Prevent Exacerbation of Chronic Obstructive Pulmonary Disease by Phosphoproteomics Analysis.Front Pharmacol. 2019 Jul 3;10:737. doi: 10.3389/fphar.2019.00737. eCollection 2019.
237 Pharmacological inhibition of protein kinase C (PKC) downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD).Eur J Pharm Sci. 2016 Oct 10;93:405-9. doi: 10.1016/j.ejps.2016.08.016. Epub 2016 Aug 8.
238 Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD.Respir Res. 2014 Apr 18;15(1):48. doi: 10.1186/1465-9921-15-48.
239 Genetic Polymorphism of CHRM2 in COPD: Clinical Significance and Therapeutic Implications.J Cell Physiol. 2016 Aug;231(8):1745-51. doi: 10.1002/jcp.25277. Epub 2016 Jan 15.
240 A functional polymorphism in the CHRNA3 gene and risk of chronic obstructive pulmonary disease in a Korean population.J Korean Med Sci. 2012 Dec;27(12):1536-40. doi: 10.3346/jkms.2012.27.12.1536. Epub 2012 Dec 7.
241 Duplicated copy of CHRNA7 increases risk and worsens prognosis of COPD and lung cancer.Eur J Hum Genet. 2015 Aug;23(8):1019-24. doi: 10.1038/ejhg.2014.229. Epub 2014 Nov 19.
242 Classical NF-B activation impairs skeletal muscle oxidative phenotype by reducing IKK- expression.Biochim Biophys Acta. 2014 Feb;1842(2):175-85. doi: 10.1016/j.bbadis.2013.11.001. Epub 2013 Nov 8.
243 Niflumic Acid Reverses Airway Mucus Excess and Improves Survival in the Rat Model of Steroid-Induced Pneumocystis Pneumonia.Front Microbiol. 2019 Jul 5;10:1522. doi: 10.3389/fmicb.2019.01522. eCollection 2019.
244 Altered skeletal muscle mitochondrial phenotype in COPD: disease vs. disuse.J Appl Physiol (1985). 2018 Apr 1;124(4):1045-1053. doi: 10.1152/japplphysiol.00788.2017. Epub 2017 Dec 28.
245 The Role of Cystathionine--Lyase In Blunt Chest Trauma in Cigarette Smoke Exposed Mice.Shock. 2017 Apr;47(4):491-499. doi: 10.1097/SHK.0000000000000746.
246 Cathepsin E promotes pulmonary emphysema via mitochondrial fission.Am J Pathol. 2014 Oct;184(10):2730-41. doi: 10.1016/j.ajpath.2014.06.017.
247 Increased levels of inflammatory biomarker CX3CL1 in patients with chronic obstructive pulmonary disease.Cytokine. 2020 Feb;126:154881. doi: 10.1016/j.cyto.2019.154881. Epub 2019 Oct 16.
248 Polarized localization of epithelial CXCL11 in chronic obstructive pulmonary disease and mechanisms of T cell egression.J Immunol. 2008 Feb 1;180(3):1866-77. doi: 10.4049/jimmunol.180.3.1866.
249 CHRNA3 and CYP3A5*3 genotype, lung function and chronic obstructive pulmonary disease in the general population.Pharmacogenet Genomics. 2014 Apr;24(4):220-9. doi: 10.1097/FPC.0000000000000038.
250 Genome-wide association study of smoking behaviours in patients with COPD.Thorax. 2011 Oct;66(10):894-902. doi: 10.1136/thoraxjnl-2011-200154. Epub 2011 Jun 16.
251 2D-DIGE proteomic analysis of vastus lateralis from COPD patients with low and normal fat free mass index and healthy controls.Respir Res. 2017 May 3;18(1):81. doi: 10.1186/s12931-017-0525-x.
252 Ursolic acid attenuates cigarette smoke-induced emphysema in rats by regulating PERK and Nrf2 pathways.Pulm Pharmacol Ther. 2017 Jun;44:111-121. doi: 10.1016/j.pupt.2017.03.014. Epub 2017 Mar 27.
253 Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease.J Allergy Clin Immunol. 2018 Jan;141(1):117-127. doi: 10.1016/j.jaci.2017.04.022. Epub 2017 May 13.
254 Cigarette Smoke-Induced Pulmonary Inflammation and Autophagy Are Attenuated in Ephx2-Deficient Mice.Inflammation. 2017 Apr;40(2):497-510. doi: 10.1007/s10753-016-0495-z.
255 Bioinformatics analysis of RNA-seq data revealed critical genes in colon adenocarcinoma.Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3012-3020.
256 The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD.Panminerva Med. 2017 Sep;59(3):203-209. doi: 10.23736/S0031-0808.17.03296-7. Epub 2017 Feb 9.
257 Blockade of RAGE ameliorates elastase-induced emphysema development and progression via RAGE-DAMP signaling.FASEB J. 2017 May;31(5):2076-2089. doi: 10.1096/fj.201601155R. Epub 2017 Feb 1.
258 The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway.Biochem Biophys Res Commun. 2010 May 28;396(2):555-61. doi: 10.1016/j.bbrc.2010.04.145. Epub 2010 May 8.
259 General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): study protocol for a randomised controlled trial.Trials. 2017 Sep 29;18(1):442. doi: 10.1186/s13063-017-2144-8.
260 IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease.Am J Respir Cell Mol Biol. 2015 Mar;52(3):365-76. doi: 10.1165/rcmb.2014-0210OC.
261 Expression and role of adrenomedullin and its receptor in patients with chronic obstructive pulmonary disease.Chin Med J (Engl). 2003 Jun;116(6):863-7.
262 Genetic variants associated with the risk of chronic obstructive pulmonary disease with and without lung cancer.Cancer Prev Res (Phila). 2012 Mar;5(3):365-73. doi: 10.1158/1940-6207.CAPR-11-0243. Epub 2011 Nov 1.
263 Hematopoietic cell kinase gene polymorphisms and the risk of chronic obstructive pulmonary disease in a Chinese population.Exp Lung Res. 2012 Feb;38(1):37-42. doi: 10.3109/01902148.2011.632062. Epub 2011 Dec 20.
264 Reduced HDAC2 in skeletal muscle of COPD patients.Respir Res. 2017 May 19;18(1):99. doi: 10.1186/s12931-017-0588-8.
265 Relationship between COPD and polymorphisms of HOX-1 and mEPH in a Chinese population.Oncol Rep. 2007 Feb;17(2):483-8.
266 Exploring the link between scavenger receptor B1 expression and chronic obstructive pulmonary disease pathogenesis.Ann N Y Acad Sci. 2015 Mar;1340:47-54. doi: 10.1111/nyas.12714. Epub 2015 Mar 12.
267 Reduced sputum expression of interferon-stimulated genes in severe COPD.Int J Chron Obstruct Pulmon Dis. 2016 Jun 30;11:1485-94. doi: 10.2147/COPD.S105948. eCollection 2016.
268 Association between single-nucleotide polymorphisms in interleukin-12A and risk of chronic obstructive pulmonary disease.DNA Cell Biol. 2012 Sep;31(9):1475-9. doi: 10.1089/dna.2012.1719. Epub 2012 Jun 26.
269 Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease.Allergy. 2010 Apr;65(4):474-81. doi: 10.1111/j.1398-9995.2009.02167.x. Epub 2009 Oct 1.
270 Increased IL-33 expression in chronic obstructive pulmonary disease.Am J Physiol Lung Cell Mol Physiol. 2015 Apr 1;308(7):L619-27. doi: 10.1152/ajplung.00305.2014. Epub 2015 Jan 16.
271 Exacerbating factors induce different gene expression profiles in peripheral blood mononuclear cells from asthmatics, patients with chronic obstructive pulmonary disease and healthy subjects.Int Arch Allergy Immunol. 2014;165(4):229-43. doi: 10.1159/000370067. Epub 2015 Jan 29.
272 Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression.Eur Respir J. 2017 May 23;49(5):1602006. doi: 10.1183/13993003.02006-2016. Print 2017 May.
273 Diagnostic and prognostic values of integrin subfamily mRNA expression in colon adenocarcinoma.Oncol Rep. 2019 Sep;42(3):923-936. doi: 10.3892/or.2019.7216. Epub 2019 Jun 28.
274 [Study of the function of leukocyte adhesion molecules in chronic respiratory diseases].Zhonghua Jie He He Hu Xi Za Zhi. 2002 Feb;25(2):94-7.
275 A genome-wide analysis of the response to inhaled 2-agonists in chronic obstructive pulmonary disease.Pharmacogenomics J. 2016 Aug;16(4):326-35. doi: 10.1038/tpj.2015.65. Epub 2015 Oct 27.
276 Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection.Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1127-L1140. doi: 10.1152/ajplung.00379.2018. Epub 2019 Mar 25.
277 Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.FASEB J. 2014 Feb;28(2):923-34. doi: 10.1096/fj.13-240879. Epub 2013 Nov 18.
278 Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease.Am J Clin Nutr. 2008 Feb;87(2):385-90. doi: 10.1093/ajcn/87.2.385.
279 Immunoglobulin A Protease Variants Facilitate Intracellular Survival in Epithelial Cells By Nontypeable Haemophilus influenzae That Persist in the Human Respiratory Tract in Chronic Obstructive Pulmonary Disease.J Infect Dis. 2017 Dec 5;216(10):1295-1302. doi: 10.1093/infdis/jix471.
280 Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.Respir Res. 2017 Mar 11;18(1):46. doi: 10.1186/s12931-017-0529-6.
281 Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations.Am J Physiol Lung Cell Mol Physiol. 2014 Aug 15;307(4):L311-6. doi: 10.1152/ajplung.00128.2014. Epub 2014 Jun 27.
282 Potential Link between the Sphingosine-1-Phosphate (S1P) System and Defective Alveolar Macrophage Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD).PLoS One. 2015 Oct 20;10(10):e0122771. doi: 10.1371/journal.pone.0122771. eCollection 2015.
283 Cigarette smoke attenuates phagocytic ability of macrophages through down-regulating Milk fat globule-EGF factor 8 (MFG-E8) expressions.Sci Rep. 2017 Feb 14;7:42642. doi: 10.1038/srep42642.
284 Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls.PLoS One. 2013 Jul 30;8(7):e70220. doi: 10.1371/journal.pone.0070220. Print 2013.
285 Suppression of NLRX1 in chronic obstructive pulmonary disease.J Clin Invest. 2015 Jun;125(6):2458-62. doi: 10.1172/JCI71747. Epub 2015 May 4.
286 NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD.Eur Respir J. 2016 Jan;47(1):254-63. doi: 10.1183/13993003.02144-2014. Epub 2015 Nov 5.
287 Extracellular adenosine triphosphate is associated with airflow limitation severity and symptoms burden in patients with chronic obstructive pulmonary disease.Sci Rep. 2019 Oct 25;9(1):15349. doi: 10.1038/s41598-019-51855-w.
288 Pri-microRNA-124 rs531564 polymorphism minor allele increases the risk of pulmonary artery hypertension by abnormally enhancing proliferation of pulmonary artery smooth muscle cells.Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1351-1361. doi: 10.2147/COPD.S99318. eCollection 2017.
289 Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.Int J Mol Sci. 2018 Nov 8;19(11):3511. doi: 10.3390/ijms19113511.
290 Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.Pulm Pharmacol Ther. 2007;20(1):60-8. doi: 10.1016/j.pupt.2005.11.010. Epub 2006 Jan 20.
291 Alpha 1 antitrypsin polymorphism in the Tunisian population with special reference to pulmonary disease.Pathol Biol (Paris). 2008 May;56(3):106-10. doi: 10.1016/j.patbio.2007.05.003. Epub 2007 Nov 26.
292 Comprehensive Analysis of miRNA-mRNA-lncRNA Networks in Non-Smoking and Smoking Patients with Chronic Obstructive Pulmonary Disease.Cell Physiol Biochem. 2018;50(3):1140-1153. doi: 10.1159/000494541. Epub 2018 Oct 24.
293 A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype.Clin Exp Allergy. 2017 Nov;47(11):1374-1382. doi: 10.1111/cea.12970. Epub 2017 Aug 1.
294 Mitogen- and stress-activated kinase 1 (MSK1) regulates cigarette smoke-induced histone modifications on NF-B-dependent genes.PLoS One. 2012;7(2):e31378. doi: 10.1371/journal.pone.0031378. Epub 2012 Feb 1.
295 Reduced DNA methylation of sphingosine-1 phosphate receptor 5 in alveolar macrophages in COPD: A potential link to failed efferocytosis.Respirology. 2017 Feb;22(2):315-321. doi: 10.1111/resp.12949. Epub 2016 Nov 20.
296 Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:981-987. doi: 10.2147/COPD.S128689. eCollection 2017.
297 alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies.Clin Sci (Lond). 2009 May 14;116(12):837-50. doi: 10.1042/CS20080484.
298 Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population.Int J Chron Obstruct Pulmon Dis. 2015 Jul 27;10:1455-63. doi: 10.2147/COPD.S86721. eCollection 2015.
299 Oxygen Desaturation in Daily Life and During a Laboratory-Based Protocol of Activities of Daily Living in COPD: Is There Relationship?.Lung. 2018 Feb;196(1):19-26. doi: 10.1007/s00408-017-0068-4. Epub 2017 Nov 13.
300 Oxidative stress dependent microRNA-34a activation via PI3K reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells.Sci Rep. 2016 Oct 21;6:35871. doi: 10.1038/srep35871.
301 Gene and metabolite time-course response to cigarette smoking in mouse lung and plasma.PLoS One. 2017 Jun 2;12(6):e0178281. doi: 10.1371/journal.pone.0178281. eCollection 2017.
302 The clinical and genetic features of COPD-asthma overlap syndrome.Eur Respir J. 2014 Aug;44(2):341-50. doi: 10.1183/09031936.00216013. Epub 2014 May 29.
303 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK- and - selectivity, suppresses COPD inflammation.Eur Respir J. 2017 Oct 26;50(4):1700188. doi: 10.1183/13993003.00188-2017. Print 2017 Oct.
304 The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD.PLoS One. 2016 Jan 11;11(1):e0146102. doi: 10.1371/journal.pone.0146102. eCollection 2016.
305 SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.Sci Rep. 2017 Apr 20;7:46667. doi: 10.1038/srep46667.
306 Genetic variants predicting aerobic capacity response to training are also associated with skeletal muscle oxidative capacity in moderate-to-severe COPD.Physiol Genomics. 2018 Sep 1;50(9):688-690. doi: 10.1152/physiolgenomics.00140.2017. Epub 2018 May 25.
307 A systemic defect in Toll-like receptor 4 signaling increases lipopolysaccharide-induced suppression of IL-2-dependent T-cell proliferation in COPD.Am J Physiol Lung Cell Mol Physiol. 2016 Jan 1;310(1):L24-39. doi: 10.1152/ajplung.00367.2014. Epub 2015 Oct 23.
308 A candidate gene identification strategy utilizing mouse to human big-data mining: "3R-tenet" in COPD genetic research.Respir Res. 2018 Jun 6;19(1):92. doi: 10.1186/s12931-018-0795-y.
309 Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease.Clin Exp Immunol. 2011 Oct;166(1):94-102. doi: 10.1111/j.1365-2249.2011.04455.x.
310 Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation.Eur Respir J. 2008 Mar;31(3):563-70. doi: 10.1183/09031936.00015807. Epub 2007 Nov 21.
311 Shelterin Telomere Protection Protein 1 Reduction Causes Telomere Attrition and Cellular Senescence via Sirtuin 1 Deacetylase in Chronic Obstructive Pulmonary Disease.Am J Respir Cell Mol Biol. 2017 Jan;56(1):38-49. doi: 10.1165/rcmb.2016-0198OC.
312 Effects of TRPC1 on epithelial mesenchymal transition in human airway in chronic obstructive pulmonary disease.Medicine (Baltimore). 2017 Oct;96(43):e8166. doi: 10.1097/MD.0000000000008166.
313 Integrating 3-omics data analyze rat lung tissue of COPD states and medical intervention by delineation of molecular and pathway alterations.Biosci Rep. 2017 Jun 21;37(3):BSR20170042. doi: 10.1042/BSR20170042. Print 2017 Jun 30.
314 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study.J Thorac Dis. 2018 Jun;10(6):3661-3669. doi: 10.21037/jtd.2018.05.139.
315 Role of Glucosylceramide in Lung Endothelial Cell Fate and Emphysema.Am J Respir Crit Care Med. 2019 Nov 1;200(9):1113-1125. doi: 10.1164/rccm.201812-2311OC.
316 Increased Myogenic and Protein Turnover Signaling in Skeletal Muscle of Chronic Obstructive Pulmonary Disease Patients With Sarcopenia.J Am Med Dir Assoc. 2017 Jul 1;18(7):637.e1-637.e11. doi: 10.1016/j.jamda.2017.04.016. Epub 2017 May 31.
317 Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.Peptides. 2010 Apr;31(4):603-8. doi: 10.1016/j.peptides.2009.12.014. Epub 2009 Dec 22.
318 Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations.J Thorac Imaging. 2019 May;34(3):160-169. doi: 10.1097/RTI.0000000000000379.
319 The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro.Pharmacol Rep. 2019 Dec;71(6):1219-1226. doi: 10.1016/j.pharep.2019.08.006. Epub 2019 Aug 17.
320 A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med. 2018 Nov 15;198(10):1254-1267. doi: 10.1164/rccm.201707-1331OC.
321 Effect of adenosine A2A receptor activation in murine models of respiratory disorders.Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L1036-43. doi: 10.1152/ajplung.00422.2005. Epub 2005 Dec 9.
322 Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting 2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan.Int J Chron Obstruct Pulmon Dis. 2018 Oct 8;13:3141-3147. doi: 10.2147/COPD.S179285. eCollection 2018.
323 Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm.J Med Genet. 2008 Nov;45(11):721-30. doi: 10.1136/jmg.2008.057851. Epub 2008 Jul 17.
324 Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats.Chin J Integr Med. 2019 Oct;25(10):750-756. doi: 10.1007/s11655-018-2577-2. Epub 2018 Dec 27.
325 The expressions and significance of APN, D-D, IL-17 and hs-CRP in patients with acute exacerbation of chronic obstructive pulmonary disease.Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6463-6468. doi: 10.26355/eurrev_201810_16059.
326 Exploring the cross-phenotype network region of disease modules reveals concordant and discordant pathways between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.Hum Mol Genet. 2019 Jul 15;28(14):2352-2364. doi: 10.1093/hmg/ddz069.
327 Bone morphogenetic protein 6 (BMP-6) modulates lung function, pulmonary iron levels and cigarette smoke-induced inflammation.Mucosal Immunol. 2019 Mar;12(2):340-351. doi: 10.1038/s41385-018-0116-2. Epub 2018 Dec 12.
328 Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma.Am J Respir Cell Mol Biol. 2004 Aug;31(2):216-9. doi: 10.1165/rcmb.2003-0394OC. Epub 2004 Mar 23.
329 Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2019 Jan 25;14:321-330. doi: 10.2147/COPD.S185602. eCollection 2019.
330 AIM2 Inflammasome Activation Leads to IL-1 and TGF- Release From Exacerbated Chronic Obstructive Pulmonary Disease-Derived Peripheral Blood Mononuclear Cells.Front Pharmacol. 2019 Mar 15;10:257. doi: 10.3389/fphar.2019.00257. eCollection 2019.
331 Hydrogen coadministration slows the development of COPD-like lung disease in a cigarette smoke-induced rat model.Int J Chron Obstruct Pulmon Dis. 2017 May 2;12:1309-1324. doi: 10.2147/COPD.S124547. eCollection 2017.
332 Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8.
333 Expression variations of connective tissue growth factor in pulmonary arteries from smokers with and without chronic obstructive pulmonary disease.Sci Rep. 2015 Feb 24;5:8564. doi: 10.1038/srep08564.
334 Activation and polarization of circulating monocytes in severe chronic obstructive pulmonary disease.BMC Pulm Med. 2018 Jun 15;18(1):101. doi: 10.1186/s12890-018-0664-y.
335 Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease.Biomed Pharmacother. 2018 Dec;108:1141-1151. doi: 10.1016/j.biopha.2018.09.113. Epub 2018 Oct 1.
336 The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics.J Clin Invest. 2001 Jun;107(11):1357-64. doi: 10.1172/JCI12655.
337 Chronic obstructive pulmonary disease patients have a higher risk of occurrence of pneumonia by air pollution.Sci Total Environ. 2019 Aug 10;677:524-529. doi: 10.1016/j.scitotenv.2019.04.358. Epub 2019 Apr 26.
338 The significance of CD163-expressing macrophages in asthma.Ann Allergy Asthma Immunol. 2019 Sep;123(3):263-270. doi: 10.1016/j.anai.2019.05.019. Epub 2019 May 30.
339 Associations of genetic polymorphisms of Siglecs with human diseases.Glycobiology. 2014 Sep;24(9):785-93. doi: 10.1093/glycob/cwu043. Epub 2014 May 19.
340 Multi-walled carbon nanotubes activate and shift polarization of pulmonary macrophages and dendritic cells in an in vivo model of chronic obstructive lung disease.Nanotoxicology. 2020 Feb;14(1):77-96. doi: 10.1080/17435390.2019.1663954. Epub 2019 Sep 26.
341 Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function.Am J Respir Crit Care Med. 2019 Jul 1;200(1):51-62. doi: 10.1164/rccm.201808-1518OC.
342 A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry.BMC Genet. 2015 Dec 3;16:138. doi: 10.1186/s12863-015-0299-4.
343 Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.Respir Res. 2019 Jan 8;20(1):4. doi: 10.1186/s12931-019-0972-7.
344 Cigarette Smoke Exposure Induces Retrograde Trafficking of CFTR to the Endoplasmic Reticulum.Sci Rep. 2019 Sep 20;9(1):13655. doi: 10.1038/s41598-019-49544-9.
345 Upregulation of Chitinase 1 in Alveolar Macrophages of HIV-Infected Smokers.J Immunol. 2019 Mar 1;202(5):1363-1372. doi: 10.4049/jimmunol.1801105. Epub 2019 Jan 21.
346 Depletion of miR-380 mitigates human bronchial epithelial cells injury to improve chronic obstructive pulmonary disease through targeting CHRNA4.Mol Cell Probes. 2020 Feb;49:101492. doi: 10.1016/j.mcp.2019.101492. Epub 2019 Dec 9.
347 Common and Rare Variants Genetic Association Analysis of Cigarettes per Day Among Ever-Smokers in Chronic Obstructive Pulmonary Disease Cases and Controls.Nicotine Tob Res. 2019 May 21;21(6):714-722. doi: 10.1093/ntr/nty095.
348 Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.Respir Med. 2019 Aug;155:51-53. doi: 10.1016/j.rmed.2019.06.023. Epub 2019 Jun 29.
349 Internally quenched fluorogenic substrates with unnatural amino acids for cathepsin G investigation.Biochimie. 2019 Nov;166:103-111. doi: 10.1016/j.biochi.2019.05.013. Epub 2019 May 16.
350 C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2014 Apr 15;189(8):966-74. doi: 10.1164/rccm.201309-1592OC.
351 p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure.Am J Physiol Lung Cell Mol Physiol. 2016 Mar 15;310(6):L496-506. doi: 10.1152/ajplung.00290.2015. Epub 2016 Jan 8.
352 NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.Front Immunol. 2019 Feb 5;10:47. doi: 10.3389/fimmu.2019.00047. eCollection 2019.
353 Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?.Antioxid Redox Signal. 2019 Oct 10;31(11):786-790. doi: 10.1089/ars.2019.7811. Epub 2019 Jul 23.
354 CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD.Clin Chim Acta. 2010 Apr 2;411(7-8):474-80. doi: 10.1016/j.cca.2009.12.018. Epub 2010 Jan 18.
355 Deficient pulmonary IFN- expression in COPD patients.PLoS One. 2019 Jun 6;14(6):e0217803. doi: 10.1371/journal.pone.0217803. eCollection 2019.
356 Human -defensin-2 production upon viral and bacterial co-infection is attenuated in COPD.PLoS One. 2017 May 10;12(5):e0175963. doi: 10.1371/journal.pone.0175963. eCollection 2017.
357 DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients.Clin Infect Dis. 2018 Jan 6;66(1):45-53. doi: 10.1093/cid/cix741.
358 COPD GWAS variant at 19q13.2 in relation with DNA methylation and gene expression.Hum Mol Genet. 2018 Jan 15;27(2):396-405. doi: 10.1093/hmg/ddx390.
359 Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD.Respir Res. 2018 May 28;19(1):103. doi: 10.1186/s12931-018-0793-0.
360 Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease.Chin Med J (Engl). 2007 Sep 5;120(17):1505-10.
361 Role of proteinase-activated receptor-1 gene polymorphisms in susceptibility to chronic obstructive pulmonary disease.Genet Mol Res. 2015 Oct 27;14(4):13215-20. doi: 10.4238/2015.October.26.18.
362 Cigarette smoke inhibits LPS-induced FABP5 expression by preventing c-Jun binding to the FABP5 promoter.PLoS One. 2017 May 18;12(5):e0178021. doi: 10.1371/journal.pone.0178021. eCollection 2017.
363 MiR-3202 protects smokers from chronic obstructive pulmonary disease through inhibiting FAIM2: An in vivo and in vitro study.Exp Cell Res. 2018 Jan 15;362(2):370-377. doi: 10.1016/j.yexcr.2017.11.038. Epub 2017 Dec 5.
364 FGF10 and Human Lung Disease Across the Life Spectrum.Front Genet. 2018 Oct 31;9:517. doi: 10.3389/fgene.2018.00517. eCollection 2018.
365 A functional variant alters binding of activating protein 1 regulating expression of FGF7 gene associated with chronic obstructive pulmonary disease.BMC Med Genet. 2019 Feb 18;20(1):33. doi: 10.1186/s12881-019-0761-7.
366 FGF23 Induction of O-Linked N-Acetylglucosamine Regulates IL-6 Secretion in Human Bronchial Epithelial Cells.Front Endocrinol (Lausanne). 2018 Nov 27;9:708. doi: 10.3389/fendo.2018.00708. eCollection 2018.
367 Overproduction of growth differentiation factor 15 promotes human rhinovirus infection and virus-induced inflammation in the lung.Am J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L514-L527. doi: 10.1152/ajplung.00324.2017. Epub 2017 Nov 30.
368 Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection.FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):81-9. doi: 10.1016/j.femsim.2004.12.008.
369 Association among genetic polymorphisms of GSTP1, HO-1, and SOD-3 and chronic obstructive pulmonary disease susceptibility.Int J Chron Obstruct Pulmon Dis. 2019 Sep 6;14:2081-2088. doi: 10.2147/COPD.S213364. eCollection 2019.
370 Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer.Pathol Oncol Res. 2020 Apr;26(2):1117-1128. doi: 10.1007/s12253-019-00661-w. Epub 2019 May 14.
371 Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.Chin Med J (Engl). 2019 Mar 5;132(5):569-576. doi: 10.1097/CM9.0000000000000107.
372 Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: A meta-analysis.Clin Genet. 2019 Jan;95(1):53-62. doi: 10.1111/cge.13373. Epub 2018 Jun 10.
373 Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD.Int J Chron Obstruct Pulmon Dis. 2019 Aug 21;14:1879-1893. doi: 10.2147/COPD.S207203. eCollection 2019.
374 Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD.Respir Res. 2014 Nov 27;15(1):145. doi: 10.1186/s12931-014-0145-7.
375 Is the Inflammasome Pathway Active in the Peripheral Blood of Sulfur Mustard-exposed Patients?.Iran J Allergy Asthma Immunol. 2019 Apr 1;18(2):218-224.
376 IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.Eur Respir J. 2019 Jul 18;54(1):1800174. doi: 10.1183/13993003.00174-2018. Print 2019 Jul.
377 T2 Biologics for Chronic Obstructive Pulmonary Disease.J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1405-1416. doi: 10.1016/j.jaip.2019.01.036.
378 Benralizumab for the Prevention of COPD Exacerbations.N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.
379 IFN Regulatory Factor 3 Potentiates Emphysematous Aggravation by Lipopolysaccharide.J Immunol. 2017 May 1;198(9):3637-3649. doi: 10.4049/jimmunol.1601069. Epub 2017 Mar 31.
380 Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.Cell. 2019 Jan 10;176(1-2):113-126.e15. doi: 10.1016/j.cell.2018.12.002.
381 Astragaloside IV Inhibits Cigarette Smoke-Induced Pulmonary Inflammation in Mice.Inflammation. 2018 Oct;41(5):1671-1680. doi: 10.1007/s10753-018-0811-x.
382 Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks.Hum Hered. 2014;78(3-4):131-9. doi: 10.1159/000365589. Epub 2014 Aug 27.
383 The genetics of smoking in individuals with chronic obstructive pulmonary disease.Respir Res. 2018 Apr 10;19(1):59. doi: 10.1186/s12931-018-0762-7.
384 Leukotriene C4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals.J Mol Cell Cardiol. 2009 Apr;46(4):579-86. doi: 10.1016/j.yjmcc.2009.01.002.
385 MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction.PLoS One. 2016 Dec 9;11(12):e0167169. doi: 10.1371/journal.pone.0167169. eCollection 2016.
386 Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases.Am J Respir Crit Care Med. 2019 Sep 1;200(5):556-564. doi: 10.1164/rccm.201810-1975TR.
387 Angiotensin-(1-7)-mediated Mas1 receptor/NF-B-p65 signaling is involved in a cigarette smoke-induced chronic obstructive pulmonary disease mouse model.Environ Toxicol. 2018 Jan;33(1):5-15. doi: 10.1002/tox.22454. Epub 2017 Sep 28.
388 MUC18 Regulates Lung Rhinovirus Infection and Inflammation.PLoS One. 2016 Oct 4;11(10):e0163927. doi: 10.1371/journal.pone.0163927. eCollection 2016.
389 Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am J Respir Crit Care Med. 2009 Nov 1;180(9):834-45. doi: 10.1164/rccm.200903-0328OC. Epub 2009 Aug 6.
390 MMP-3 (-1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)-3 and correlate with severity of COPD: A study of MMP-3, MMP-7 and MMP-12 in a Tunisian population.J Gene Med. 2018 Jan;20(1). doi: 10.1002/jgm.2999. Epub 2017 Dec 29.
391 Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.J Immunol Res. 2017;2017:5273201. doi: 10.1155/2017/5273201. Epub 2017 May 15.
392 Function of macrophage scavenger receptor 1 gene polymorphisms in chronic obstructive pulmonary disease with and without lung cancer in China.Oncol Lett. 2018 May;15(5):8046-8052. doi: 10.3892/ol.2018.8311. Epub 2018 Mar 21.
393 Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition.Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L897-908. doi: 10.1152/ajplung.00116.2005. Epub 2005 Dec 16.
394 Association of NLRP1 Coding Polymorphism with Lung Function and Serum IL-1 Concentration in Patients Diagnosed with Chronic Obstructive Pulmonary Disease (COPD).Genes (Basel). 2019 Oct 9;10(10):783. doi: 10.3390/genes10100783.
395 Expression of Nitric Oxide Synthase Isoenzyme in Lung Tissue of Smokers with and without Chronic Obstructive Pulmonary Disease.Chin Med J (Engl). 2015 Jun 20;128(12):1584-9. doi: 10.4103/0366-6999.158309.
396 Association of brain natriuretic peptide gene polymorphisms with chronic obstructive pulmonary disease complicated with pulmonary hypertension and its mechanism.Biosci Rep. 2018 Oct 2;38(5):BSR20180905. doi: 10.1042/BSR20180905. Print 2018 Oct 31.
397 Transcriptional down-regulation of neurotrophin-3 in chronic obstructive pulmonary disease.Biol Chem. 2005 Jan;386(1):53-9. doi: 10.1515/BC.2005.007.
398 TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.Eur J Pharmacol. 2019 Apr 15;849:22-29. doi: 10.1016/j.ejphar.2019.01.068. Epub 2019 Feb 1.
399 Up-regulation of Pim-3 in Chronic Obstructive Pulmonary Disease (COPD) patients and its potential therapeutic role in COPD rat modeling.Pathol Res Pract. 2017 Apr;213(4):322-326. doi: 10.1016/j.prp.2017.01.018. Epub 2017 Jan 29.
400 Molecular modeling of Gly80 and Ser80 variants of human group IID phospholipase A2 and their receptor complexes: potential basis for weight loss in chronic obstructive pulmonary disease.J Mol Model. 2016 Sep;22(9):232. doi: 10.1007/s00894-016-3095-9. Epub 2016 Sep 1.
401 Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.Lung. 2019 Apr;197(2):189-197. doi: 10.1007/s00408-019-00211-w. Epub 2019 Feb 28.
402 [Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease].Zhonghua Jie He He Hu Xi Za Zhi. 2007 May;30(5):363-7.
403 Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases.Respir Res. 2018 Sep 20;19(1):180. doi: 10.1186/s12931-018-0883-z.
404 Identification of differentially expressed genes and signaling pathways in chronic obstructive pulmonary disease via bioinformatic analysis.FEBS Open Bio. 2019 Nov;9(11):1880-1899. doi: 10.1002/2211-5463.12719. Epub 2019 Sep 29.
405 Susceptibility loci in lung cancer and COPD: association of IREB2 and FAM13A with pulmonary diseases.Sci Rep. 2015 Aug 27;5:13502. doi: 10.1038/srep13502.
406 Increased expression of the epithelial anion transporter pendrin/SLC26A4 in nasal polyps of patients with chronic rhinosinusitis.J Allergy Clin Immunol. 2015 Dec;136(6):1548-1558.e7. doi: 10.1016/j.jaci.2015.05.024. Epub 2015 Jul 2.
407 Association of HTR2A-1438G/A Genetic Polymorphism With Smoking and Chronic Obstructive Pulmonary Disease.Arch Bronconeumol (Engl Ed). 2019 Mar;55(3):128-133. doi: 10.1016/j.arbres.2018.07.021. Epub 2018 Sep 12.
408 SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke.Biol Chem. 2004 Jul;385(7):649-53. doi: 10.1515/BC.2004.080.
409 IL-13-driven pulmonary emphysema leads to skeletal muscle dysfunction attenuated by endurance exercise.J Appl Physiol (1985). 2020 Jan 1;128(1):134-148. doi: 10.1152/japplphysiol.00627.2019. Epub 2019 Nov 27.
410 Transcription regulation of NRF1 on StAR reduces testosterone synthesis in hypoxemic murine.J Steroid Biochem Mol Biol. 2019 Jul;191:105370. doi: 10.1016/j.jsbmb.2019.04.019. Epub 2019 Apr 24.
411 Liuweibuqi capsules improve pulmonary function in stable chronic obstructive pulmonary disease with lung-qi deficiency syndrome by regulating STAT4/STAT6 and MMP-9/TIMP-1.Pharm Biol. 2019 Dec;57(1):744-752. doi: 10.1080/13880209.2019.1666151.
412 Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis.Lancet Respir Med. 2014 Mar;2(3):214-25. doi: 10.1016/S2213-2600(14)70002-5. Epub 2014 Feb 7.
413 Pro-inflammatory effects of extracellular Hsp70 and cigarette smoke in primary airway epithelial cells from COPD patients.Biochimie. 2019 Jan;156:47-58. doi: 10.1016/j.biochi.2018.09.010. Epub 2018 Sep 27.
414 Association of Respiratory Syncytial Virus Toll-Like Receptor 3-Mediated Immune Response with COPD Exacerbation Frequency.Inflammation. 2018 Mar;41(2):654-666. doi: 10.1007/s10753-017-0720-4.
415 Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease.BMC Med Genet. 2005 Sep 28;6:34. doi: 10.1186/1471-2350-6-34.
416 TRPV4-mediated calcium influx into human bronchial epithelia upon exposure to diesel exhaust particles.Environ Health Perspect. 2011 Jun;119(6):784-93. doi: 10.1289/ehp.1002807. Epub 2011 Jan 18.
417 Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis: A pilot study.Clin Respir J. 2019 Oct;13(10):652-656. doi: 10.1111/crj.13075. Epub 2019 Aug 19.
418 Effect of physical therapy for chronic obstructive pulmonary disease: A protocol for an updated systematic review of randomized controlled trial.Medicine (Baltimore). 2019 Sep;98(38):e17241. doi: 10.1097/MD.0000000000017241.
419 Association of XRCC5 polymorphisms with COPD and COPD-related phenotypes in the Han Chinese population: a case-control cohort study.Genet Mol Res. 2014 Jan 24;13(3):7070-8. doi: 10.4238/2014.January.24.11.
420 Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study.Eur J Pharm Sci. 2018 Jul 30;120:96-106. doi: 10.1016/j.ejps.2018.04.042. Epub 2018 Apr 30.
421 IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).J Thorac Oncol. 2016 Dec;11(12):2183-2192. doi: 10.1016/j.jtho.2016.07.026. Epub 2016 Aug 12.
422 SLC11A1 polymorphisms are associated with the risk of chronic obstructive pulmonary disease in a Korean population.Biochem Genet. 2008 Aug;46(7-8):506-19. doi: 10.1007/s10528-008-9166-6. Epub 2008 May 27.
423 Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2012 Dec 15;186(12):1238-47. doi: 10.1164/rccm.201206-1013OC. Epub 2012 Nov 9.
424 Association between vertebral fractures and coronary artery calcification in current and former smokers in the ECLIPSE cohort.Osteoporos Int. 2020 Feb;31(2):297-305. doi: 10.1007/s00198-019-05218-w. Epub 2019 Nov 25.
425 Cholesterol metabolism promotes B-cell positioning during immune pathogenesis of chronic obstructive pulmonary disease.EMBO Mol Med. 2018 May;10(5):e8349. doi: 10.15252/emmm.201708349.
426 The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model.Eur Respir J. 2018 Sep 15;52(3):1800079. doi: 10.1183/13993003.00079-2018. Print 2018 Sep.
427 Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease.Clin Chim Acta. 2007 Jul;382(1-2):37-42. doi: 10.1016/j.cca.2007.03.013. Epub 2007 Mar 24.
428 The effect of diesel emission exposure on primary human bronchial epithelial cells from a COPD cohort: N-acetylcysteine as a potential protective intervention.Environ Res. 2019 Mar;170:194-202. doi: 10.1016/j.envres.2018.12.035. Epub 2018 Dec 18.
429 Early Invasive Versus Ischemia-Guided Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome With Chronic Obstructive Pulmonary Disease: A National Inpatient Sample Analysis.Angiology. 2020 Apr;71(4):372-379. doi: 10.1177/0003319719877096. Epub 2019 Oct 2.
430 AEBP1, a prognostic indicator, promotes colon adenocarcinoma cell growth and metastasis through the NF-B pathway.Mol Carcinog. 2019 Oct;58(10):1795-1808. doi: 10.1002/mc.23066. Epub 2019 Jun 10.
431 Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.Nat Genet. 2017 Mar;49(3):426-432. doi: 10.1038/ng.3752. Epub 2017 Feb 6.
432 Multibreath Hyperpolarized (3)He Imaging Scheme to Measure Alveolar Oxygen Tension and Apparent Diffusion Coefficient.Acad Radiol. 2019 Mar;26(3):367-382. doi: 10.1016/j.acra.2018.10.001. Epub 2019 Jan 8.
433 Exaggerated BMP4 signalling alters human airway basal progenitor celldifferentiation to cigarette smoking-related phenotypes.Eur Respir J. 2019 May 18;53(5):1702553. doi: 10.1183/13993003.02553-2017. Print 2019 May.
434 PMN degranulation in relation to CD63 expression and genetic polymorphisms in healthy individuals and COPD patients.Int J Mol Med. 2007 May;19(5):817-22. doi: 10.3892/ijmm.19.5.817.
435 Double deletion of tetraspanins CD9 and CD81 in mice leads to a syndrome resembling accelerated aging.Sci Rep. 2018 Mar 23;8(1):5145. doi: 10.1038/s41598-018-23338-x.
436 Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort.Respir Res. 2019 Apr 1;20(1):63. doi: 10.1186/s12931-019-1026-x.
437 The cullin4A is up-regulated in chronic obstructive pulmonary disease patient and contributes to epithelial-mesenchymal transition in small airway epithelium.Respir Res. 2019 May 6;20(1):84. doi: 10.1186/s12931-019-1048-4.
438 Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma.J Cell Physiol. 2020 May;235(5):4902-4912. doi: 10.1002/jcp.29368. Epub 2019 Nov 10.
439 Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox.Eur Respir J. 2017 Jul 20;50(1):1601651. doi: 10.1183/13993003.01651-2016. Print 2017 Jul.
440 Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients.Sci Rep. 2019 Oct 30;9(1):15682. doi: 10.1038/s41598-019-52179-5.
441 Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study.Korean J Intern Med. 2019 Nov;34(6):1272-1278. doi: 10.3904/kjim.2017.428. Epub 2019 Oct 16.
442 Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.Vaccine. 2019 Sep 24;37(41):6102-6111. doi: 10.1016/j.vaccine.2019.07.100. Epub 2019 Aug 22.
443 Association of serum deiodinase type 2 level with chronic obstructive pulmonary disease in the Polish population.Acta Biochim Pol. 2019 Apr 12;66(2). doi: 10.18388/abp.2018_2761.
444 A genome-wide association study of chronic obstructive pulmonary disease in Hispanics.Ann Am Thorac Soc. 2015 Mar;12(3):340-8. doi: 10.1513/AnnalsATS.201408-380OC.
445 Long non-coding RNA TUG1 promotes airway remodelling by suppressing the miR-145-5p/DUSP6 axis in cigarette smoke-induced COPD.J Cell Mol Med. 2019 Nov;23(11):7200-7209. doi: 10.1111/jcmm.14389. Epub 2019 Sep 26.
446 End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort.Respir Med. 2019 Nov-Dec;160:105814. doi: 10.1016/j.rmed.2019.105814. Epub 2019 Nov 6.
447 Analysis of genetically driven alternative splicing identifies FBXO38 as a novel COPD susceptibility gene.PLoS Genet. 2019 Jul 3;15(7):e1008229. doi: 10.1371/journal.pgen.1008229. eCollection 2019 Jul.
448 Silencing FUNDC1 alleviates chronic obstructive pulmonary disease by inhibiting mitochondrial autophagy and bronchial epithelium cell apoptosis under hypoxic environment.J Cell Biochem. 2019 Oct;120(10):17602-17615. doi: 10.1002/jcb.29028. Epub 2019 Jun 25.
449 Impaired Skeletal Muscle Kynurenine Metabolism in Patients with Chronic Obstructive Pulmonary Disease.J Clin Med. 2019 Jun 26;8(7):915. doi: 10.3390/jcm8070915.
450 G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.J Thorac Oncol. 2012 Dec;7(12):1747-1754. doi: 10.1097/JTO.0b013e31826bb1ff.
451 Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2007 Mar 1;175(5):464-72. doi: 10.1164/rccm.200602-169OC. Epub 2006 Nov 30.
452 Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients.Int J Chron Obstruct Pulmon Dis. 2018 Oct 12;13:3173-3190. doi: 10.2147/COPD.S166284. eCollection 2018.
453 Serum levels of hyaluronic acid are associated with COPD severity and predict survival.Eur Respir J. 2019 Mar 7;53(3):1801183. doi: 10.1183/13993003.01183-2018. Print 2019 Mar.
454 Polymorphisms of interleukin-10 and its receptor and lung function in COPD.Eur Respir J. 2007 Jun;29(6):1120-6. doi: 10.1183/09031936.00002907. Epub 2007 Mar 1.
455 miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.Int J Chron Obstruct Pulmon Dis. 2018 Nov 20;13:3777-3790. doi: 10.2147/COPD.S182504. eCollection 2018.
456 Low Vitamin K Status Is Associated with Increased Elastin Degradation in Chronic Obstructive Pulmonary Disease.J Clin Med. 2019 Jul 27;8(8):1116. doi: 10.3390/jcm8081116.
457 Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review.Eur Respir Rev. 2019 Mar 27;28(151):180096. doi: 10.1183/16000617.0096-2018. Print 2019 Mar 31.
458 Two Interventions for Patients with Major Depression and Severe Chronic Obstructive Pulmonary Disease: Impact on Dyspnea-Related Disability.Am J Geriatr Psychiatry. 2018 Feb;26(2):162-171. doi: 10.1016/j.jagp.2017.10.002. Epub 2017 Oct 10.
459 The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly.Cancer Med. 2019 Aug;8(9):4124-4134. doi: 10.1002/cam4.2333. Epub 2019 Jun 11.
460 Bronchial Epithelial Calcium Metabolism Impairment in Smokers and Chronic Obstructive Pulmonary Disease. Decreased ORAI3 Signaling.Am J Respir Cell Mol Biol. 2019 Oct;61(4):501-511. doi: 10.1165/rcmb.2018-0228OC.
461 A Genome-Wide Association Study in Hispanics/Latinos Identifies Novel Signals for Lung Function. The Hispanic Community Health Study/Study of Latinos.Am J Respir Crit Care Med. 2018 Jul 15;198(2):208-219. doi: 10.1164/rccm.201707-1493OC.
462 Serum levels and gene expression of pentraxin 3 are elevated in COPD.Adv Med Sci. 2019 Mar;64(1):85-89. doi: 10.1016/j.advms.2018.08.006. Epub 2018 Dec 17.
463 Whole-genome methylation profiling from PBMCs in acute-exacerbation COPD patients with good and poor responses to corticosteroid treatment.Genomics. 2019 Dec;111(6):1381-1386. doi: 10.1016/j.ygeno.2018.09.010. Epub 2018 Sep 21.
464 EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population.Int J Chron Obstruct Pulmon Dis. 2015 Jan 13;10:145-51. doi: 10.2147/COPD.S73031. eCollection 2015.
465 Roundabout signaling pathway involved in the pathogenesis of COPD by integrative bioinformatics analysis.Int J Chron Obstruct Pulmon Dis. 2019 Sep 18;14:2145-2162. doi: 10.2147/COPD.S216050. eCollection 2019.
466 Increased Serum Romo1 Was Correlated with Lung Function, Inflammation, and Oxidative Stress in Chronic Obstructive Pulmonary Disease.Inflammation. 2019 Oct;42(5):1555-1560. doi: 10.1007/s10753-019-01017-x.
467 The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature.Eur J Health Econ. 2020 Mar;21(2):181-194. doi: 10.1007/s10198-019-01119-1. Epub 2019 Sep 28.
468 Breathing Out Completely Before Inhalation: The Most Problematic Step in Application Technique in Patients With Non-Mild Chronic Obstructive Pulmonary Disease.Front Pharmacol. 2019 Mar 12;10:241. doi: 10.3389/fphar.2019.00241. eCollection 2019.
469 Improving recruitment to a study of telehealth management for COPD: a cluster randomised controlled 'study within a trial' (SWAT) of a multimedia information resource.Trials. 2019 Jul 24;20(1):453. doi: 10.1186/s13063-019-3496-z.
470 Expression of Hippo pathway genes and their clinical significance in colon adenocarcinoma.Oncol Lett. 2018 Apr;15(4):4926-4936. doi: 10.3892/ol.2018.7911. Epub 2018 Jan 31.
471 TNNT1, a prognostic indicator in colon adenocarcinoma, regulates cell behaviors and mediates EMT process.Biosci Biotechnol Biochem. 2020 Jan;84(1):111-117. doi: 10.1080/09168451.2019.1664891. Epub 2019 Sep 12.
472 Identification of potential key genes associated with severe pneumonia using mRNA-seq.Exp Ther Med. 2018 Aug;16(2):758-766. doi: 10.3892/etm.2018.6262. Epub 2018 Jun 7.
473 The Notch ligand DNER regulates macrophage IFN release in chronic obstructive pulmonary disease.EBioMedicine. 2019 May;43:562-575. doi: 10.1016/j.ebiom.2019.03.054. Epub 2019 May 4.
474 Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications.Curr Opin Pulm Med. 2011 Dec;17 Suppl 1:S11-9. doi: 10.1097/01.mcp.0000410743.98087.12.
475 Associations of ABHD2 genetic variations with risks for chronic obstructive pulmonary disease in a Chinese Han population.PLoS One. 2015 Apr 16;10(4):e0123929. doi: 10.1371/journal.pone.0123929. eCollection 2015.
476 Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction.Am J Respir Crit Care Med. 2012 Oct 1;186(7):622-32. doi: 10.1164/rccm.201202-0366OC. Epub 2012 Jul 26.
477 Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease.Int J Biochem Cell Biol. 2012 Mar;44(3):563-9. doi: 10.1016/j.biocel.2011.12.016. Epub 2012 Jan 3.
478 XB130 translocation to microfilamentous structures mediates NNK-induced migration of human bronchial epithelial cells.Oncotarget. 2015 Jul 20;6(20):18050-65. doi: 10.18632/oncotarget.3777.
479 A-kinase-anchoring proteins coordinate inflammatory responses to cigarette smoke in airway smooth muscle.Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L766-75. doi: 10.1152/ajplung.00301.2014. Epub 2015 Jan 30.
480 Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema.J Mol Med (Berl). 2011 Jun;89(6):577-93. doi: 10.1007/s00109-011-0732-8. Epub 2011 Feb 12.
481 The role of tumor necrosis factor- and interferon- in regulating angiomotin-like protein 1 expression in lung microvascular endothelial cells.Allergol Int. 2013 Sep;62(3):309-22. doi: 10.2332/allergolint.12-OA-0528. Epub 2013 Jun 25.
482 Apolipoprotein M gene single nucleotide polymorphisms discovery in patients with chronic obstructive pulmonary disease and determined by the base-quenched probe technique.Gene. 2017 Dec 30;637:9-13. doi: 10.1016/j.gene.2017.09.029. Epub 2017 Sep 18.
483 Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns.Am J Respir Crit Care Med. 2014 Aug 15;190(4):399-409. doi: 10.1164/rccm.201403-0569OC.
484 TGF-/BAMBI pathway dysfunction contributes to peripheral Th17/Treg imbalance in chronic obstructive pulmonary disease.Sci Rep. 2016 Aug 23;6:31911. doi: 10.1038/srep31911.
485 Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema.Am J Respir Crit Care Med. 2011 Jan 1;183(1):43-9. doi: 10.1164/rccm.201004-0541OC. Epub 2010 Aug 13.
486 Dose selection for glycopyrrolate/eFlow() phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Diseasevia Electronic Nebulizer) phase II dose-finding studies.Respir Res. 2017 Dec 4;18(1):202. doi: 10.1186/s12931-017-0681-z.
487 Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD.Int J Chron Obstruct Pulmon Dis. 2017 Dec 19;13:11-27. doi: 10.2147/COPD.S144136. eCollection 2018.
488 Serum amyloid A, protein Z, and C4b-binding protein chain as new potential biomarkers for pulmonary tuberculosis.PLoS One. 2017 Mar 9;12(3):e0173304. doi: 10.1371/journal.pone.0173304. eCollection 2017.
489 Analysis of protein-protein interaction network in chronic obstructive pulmonary disease.Genet Mol Res. 2014 Oct 31;13(4):8862-9. doi: 10.4238/2014.October.31.1.
490 Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array.Cytokine. 2018 Nov;111:342-349. doi: 10.1016/j.cyto.2018.09.005. Epub 2018 Sep 28.
491 Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.Int J Chron Obstruct Pulmon Dis. 2017 Jan 5;12:199-208. doi: 10.2147/COPD.S118424. eCollection 2017.
492 Upregulation of MicroRNA-214 Contributes to the Development of Vascular Remodeling in Hypoxia-induced Pulmonary Hypertension Via Targeting CCNL2.Sci Rep. 2016 Jul 6;6:24661. doi: 10.1038/srep24661.
493 Deficiency of innate-like T lymphocytes in chronic obstructive pulmonary disease.Respir Res. 2017 Nov 28;18(1):197. doi: 10.1186/s12931-017-0671-1.
494 Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD.Respir Res. 2013 Mar 5;14(1):30. doi: 10.1186/1465-9921-14-30.
495 CD8+ T cells contribute to macrophage accumulation and airspace enlargement following repeated irritant exposure.Exp Mol Pathol. 2007 Dec;83(3):301-10. doi: 10.1016/j.yexmp.2007.08.020. Epub 2007 Sep 26.
496 A novel polymorphism in CDC6 is associated with the decline in lung function of ex-smokers in COPD.Biochem Biophys Res Commun. 2009 Apr 17;381(4):554-9. doi: 10.1016/j.bbrc.2009.02.080. Epub 2009 Feb 20.
497 Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women.Am J Respir Cell Mol Biol. 2017 Mar;56(3):332-341. doi: 10.1165/rcmb.2016-0172OC.
498 Home Non-Invasive Ventilation for COPD: How, Who and When?.Arch Bronconeumol (Engl Ed). 2018 Mar;54(3):149-154. doi: 10.1016/j.arbres.2017.12.005. Epub 2018 Jan 19.
499 Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer.J Thorac Oncol. 2015 Aug;10(8):1181-8. doi: 10.1097/JTO.0000000000000592.
500 miR-483-5p plays a protective role in chronic obstructive pulmonary disease.Int J Mol Med. 2017 Jul;40(1):193-200. doi: 10.3892/ijmm.2017.2996. Epub 2017 May 18.
501 Genetic variations in scavenger and ?adrenergic receptors and risk of pulmonary disease.Dan Med J. 2014 Sep;61(9):B4910.
502 Cold-inducible RNA-binding protein mediates airway inflammation and mucus hypersecretion through a post-transcriptional regulatory mechanism under cold stress.Int J Biochem Cell Biol. 2016 Sep;78:335-348. doi: 10.1016/j.biocel.2016.07.029. Epub 2016 Jul 28.
503 Impact of the Endothelial Tight Junction Protein Claudin-5 on Clinical Profiles of Patients With COPD.Allergy Asthma Immunol Res. 2018 Sep;10(5):533-542. doi: 10.4168/aair.2018.10.5.533.
504 HMGB1 mediates Aspergillus fumigatus-induced inflammatory response in alveolar macrophages of COPD mice via activating MyD88/NF-B and syk/PI3K signalings.Int Immunopharmacol. 2017 Dec;53:125-132. doi: 10.1016/j.intimp.2017.10.007.
505 Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis.Eur Respir J. 2014 Oct;44(4):860-72. doi: 10.1183/09031936.00001914. Epub 2014 Jul 3.
506 Failed upregulation of TFAM protein and mitochondrial DNA in oxidatively deficient fibers of chronic obstructive pulmonary disease locomotor muscle.Skelet Muscle. 2016 Feb 18;6:10. doi: 10.1186/s13395-016-0083-9. eCollection 2016.
507 Chemokine expression by small sputum macrophages in COPD.Mol Med. 2011;17(7-8):762-70. doi: 10.2119/molmed.2010.00202. Epub 2011 Feb 9.
508 Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine).PLoS One. 2017 May 18;12(5):e0177218. doi: 10.1371/journal.pone.0177218. eCollection 2017.
509 Correlation of vitamin D binding protein gene polymorphism and protein levels in chronic obstructive pulmonary disease compared with non-chronic obstructive pulmonary disease subjects.Per Med. 2018 Sep;15(5):371-379. doi: 10.2217/pme-2018-0005. Epub 2018 Sep 27.
510 DYX1C1 is required for axonemal dynein assembly and ciliary motility. Nat Genet. 2013 Sep;45(9):995-1003. doi: 10.1038/ng.2707. Epub 2013 Jul 21.
511 Dual oxidase 1 and 2 expression in airway epithelium of smokers and patients with mild/moderate chronic obstructive pulmonary disease.Antioxid Redox Signal. 2008 Apr;10(4):705-14. doi: 10.1089/ars.2007.1941.
512 Activation of WNT/-catenin signaling in pulmonary fibroblasts by TGF-?is increased in chronic obstructive pulmonary disease.PLoS One. 2011;6(9):e25450. doi: 10.1371/journal.pone.0025450. Epub 2011 Sep 30.
513 Elastin-Specific Autoimmunity in Smokers With Thoracic Aortic Aneurysm and Dissection is Independent of Chronic Obstructive Pulmonary Disease.J Am Heart Assoc. 2019 Apr 16;8(8):e011671. doi: 10.1161/JAHA.118.011671.
514 Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1284-1290. doi: 10.1016/j.bbrc.2018.07.038. Epub 2018 Jul 11.
515 Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD.J Pathol. 2013 Aug;230(4):388-98. doi: 10.1002/path.4197.
516 Differential regulation of extracellular matrix and soluble fibulin-1 levels by TGF-?in airway smooth muscle cells.PLoS One. 2013 Jun 7;8(6):e65544. doi: 10.1371/journal.pone.0065544. Print 2013.
517 A large lung gene expression study identifying fibulin-5 as a novel player in tissue repair in COPD.Thorax. 2015 Jan;70(1):21-32. doi: 10.1136/thoraxjnl-2014-205091. Epub 2014 Jul 2.
518 1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD).Biochem Biophys Res Commun. 2012 Jul 20;424(1):112-7. doi: 10.1016/j.bbrc.2012.06.081. Epub 2012 Jun 23.
519 Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease.Respir Med. 2017 Mar;124:72-78. doi: 10.1016/j.rmed.2017.02.011. Epub 2017 Feb 17.
520 Increased expression of heat shock protein 70 in chronic obstructive pulmonary disease.Int Immunopharmacol. 2013 Nov;17(3):885-93. doi: 10.1016/j.intimp.2013.09.003. Epub 2013 Oct 3.
521 HSP60 activity on human bronchial epithelial cells.Int J Immunopathol Pharmacol. 2017 Dec;30(4):333-340. doi: 10.1177/0394632017734479. Epub 2017 Oct 4.
522 Human Metapneumovirus Infection in Chronic Obstructive Pulmonary Disease: Impact of Glucocorticosteroids and Interferon.J Infect Dis. 2017 May 15;215(10):1536-1545. doi: 10.1093/infdis/jix167.
523 Effects of hypoxia on adipose tissue expression of NFB, IB, IKK and IKAP in patients with chronic obstructive pulmonary disease.Cell Biochem Biophys. 2013 May;66(1):7-12. doi: 10.1007/s12013-012-9391-9.
524 Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study.Medicine (Baltimore). 2016 Apr;95(15):e3371. doi: 10.1097/MD.0000000000003371.
525 Role of IL-17A in murine models of COPD airway disease.Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L122-L130. doi: 10.1152/ajplung.00301.2016. Epub 2016 Dec 2.
526 Increased IL-17RA and IL-17RC in End-Stage COPD and the Contribution to Mast Cell Secretion of FGF-2 and VEGF.Respir Res. 2017 Mar 15;18(1):48. doi: 10.1186/s12931-017-0534-9.
527 Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.Int J Chron Obstruct Pulmon Dis. 2019 Nov 29;14:2681-2695. doi: 10.2147/COPD.S216072. eCollection 2019.
528 Reduced Frizzled Receptor 4 Expression Prevents WNT/-Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med. 2017 Jul 15;196(2):172-185. doi: 10.1164/rccm.201605-0904OC.
529 miR-145-5p is associated with smoke-related chronic obstructive pulmonary disease via targeting KLF5.Chem Biol Interact. 2019 Feb 25;300:82-90. doi: 10.1016/j.cbi.2019.01.011. Epub 2019 Jan 9.
530 Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study.BMC Pulm Med. 2018 Jan 25;18(1):16. doi: 10.1186/s12890-017-0571-7.
531 Increased Circulating Autoantibodies Levels of IgG, IgA, IgM Against Cytokeratin 18 and Cytokeratin 19 in Chronic Obstructive Pulmonary Disease.Arch Med Res. 2017 Jan;48(1):79-87. doi: 10.1016/j.arcmed.2017.01.007.
532 Novel genes for airway wall thickness identified with combined genome-wide association and expression analyses.Am J Respir Crit Care Med. 2015 Mar 1;191(5):547-56. doi: 10.1164/rccm.201405-0840OC.
533 Epithelial-Immune Cell Interactions for Drug Discovery in Chronic Obstructive Pulmonary Disease.Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S260-S265. doi: 10.1513/AnnalsATS.201808-531MG.
534 Association of MicroRNA-196a2 Variant with Response to Short-Acting 2-Agonist in COPD: An Egyptian Pilot Study.PLoS One. 2016 Apr 4;11(4):e0152834. doi: 10.1371/journal.pone.0152834. eCollection 2016.
535 Pulmonary Rehabilitation Outcomes after Single or Double Lung Transplantation in Patients with Chronic Obstructive Pulmonary Disease or Interstitial Lung Disease.Respiration. 2017;94(2):178-185. doi: 10.1159/000477351. Epub 2017 Jun 10.
536 Comprehensive analysis of microRNA/mRNA signature in colon adenocarcinoma.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2114-2129.
537 Airway mucus hypersecretion in asthma: an undervalued pathology?.Curr Opin Pharmacol. 2004 Jun;4(3):241-50. doi: 10.1016/j.coph.2004.01.011.
538 Effect of polymorphisms in the 2-adrenergic receptor on the susceptibility and pulmonary function of patients with chronic obstructive pulmonary disease: a meta analysis.Chin Med J (Engl). 2012 Jun;125(12):2213-8.
539 Whole exome sequencing identifies novel candidate genes that modify chronic obstructive pulmonary disease susceptibility.Hum Genomics. 2016 Jan 7;10:1. doi: 10.1186/s40246-015-0058-7.
540 Candidate genes for COPD in two large data sets.Eur Respir J. 2011 Feb;37(2):255-63. doi: 10.1183/09031936.00091709. Epub 2010 Jun 18.
541 Raw BIA variables are predictors of muscle strength in patients with chronic obstructive pulmonary disease.Eur J Clin Nutr. 2017 Nov;71(11):1336-1340. doi: 10.1038/ejcn.2017.147. Epub 2017 Sep 13.
542 Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10662-70. eCollection 2015.
543 Single-nucleotide polymorphisms in the TSPYL-4 and NT5DC1 genes are associated with susceptibility to chronic obstructive pulmonary disease.Mol Med Rep. 2012 Sep;6(3):631-8. doi: 10.3892/mmr.2012.964. Epub 2012 Jun 25.
544 Physical Activity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease.Med Sci Sports Exerc. 2019 May;51(5):833-840. doi: 10.1249/MSS.0000000000001859.
545 Genetic variations in detoxification enzymes and HIF-1 in Japanese patients with COPD.Clin Respir J. 2013 Jan;7(1):7-15. doi: 10.1111/j.1752-699X.2011.00255.x. Epub 2011 Jul 6.
546 Pellino-1 Regulates Immune Responses to Haemophilus influenzae in Models of Inflammatory Lung Disease.Front Immunol. 2019 Jul 31;10:1721. doi: 10.3389/fimmu.2019.01721. eCollection 2019.
547 Role of miR-195 in cigarette smoke-induced chronic obstructive pulmonary disease.Int Immunopharmacol. 2018 Feb;55:49-54. doi: 10.1016/j.intimp.2017.11.030. Epub 2017 Dec 22.
548 Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells.Respiration. 2005 Nov-Dec;72(6):629-35. doi: 10.1159/000089579.
549 Association of lung function genes with chronic obstructive pulmonary disease.Lung. 2014 Aug;192(4):473-80. doi: 10.1007/s00408-014-9579-4. Epub 2014 Apr 16.
550 Gly80Ser polymorphism of phospholipase A2-IID is associated with cytokine inducibility in A549 cells.Respiration. 2009;78(3):312-21. doi: 10.1159/000213243. Epub 2009 Apr 10.
551 A Genome-Wide Linkage Study for Chronic Obstructive Pulmonary Disease in a Dutch Genetic Isolate Identifies Novel Rare Candidate Variants.Front Genet. 2018 Apr 19;9:133. doi: 10.3389/fgene.2018.00133. eCollection 2018.
552 Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects.Am J Respir Cell Mol Biol. 2017 Jul;57(1):35-46. doi: 10.1165/rcmb.2016-0331OC.
553 Diesel exhaust alters the response of cultured primary bronchial epithelial cells from patients with chronic obstructive pulmonary disease (COPD) to non-typeable Haemophilus influenzae.Respir Res. 2017 Jan 28;18(1):27. doi: 10.1186/s12931-017-0510-4.
554 Prevalence and risk factors of chronic obstructive pulmonary diseases in a Hlai community in Hainan Island of China.Clin Respir J. 2018 Jan;12(1):126-133. doi: 10.1111/crj.12497. Epub 2016 Jun 21.
555 Mechanisms of oxidative stress effects of the NADPH oxidase-ROS-NF-B transduction pathway and VPO1 on patients with chronic obstructive pulmonary disease combined with pulmonary hypertension.Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3459-3464.
556 Reduced nuclear translocation of serum response factor is associated with skeletal muscle atrophy in a cigarette smoke-induced mouse model of COPD.Int J Chron Obstruct Pulmon Dis. 2017 Feb 20;12:581-587. doi: 10.2147/COPD.S109243. eCollection 2017.
557 Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease.Front Immunol. 2018 Jun 21;9:1431. doi: 10.3389/fimmu.2018.01431. eCollection 2018.
558 Application of Inflammatory Markers in Induced Sputum in Stable Chronic Obstructive Pulmonary Disease Patients with Positive Bronchodilation Tests.Curr Med Sci. 2019 Aug;39(4):560-567. doi: 10.1007/s11596-019-2074-7. Epub 2019 Jul 25.
559 Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury.Mol Ther Nucleic Acids. 2018 Sep 7;12:370-380. doi: 10.1016/j.omtn.2018.05.027. Epub 2018 Jul 3.
560 SARCOPENIA: AN ENDOCRINE DISORDER?.Endocr Pract. 2017 Sep;23(9):1140-1149. doi: 10.4158/EP171795.RA. Epub 2017 Jul 13.
561 Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2017 May 25;12:1549-1564. doi: 10.2147/COPD.S137806. eCollection 2017.
562 Functional polymorphisms in surfactant protein genes and chronic obstructive pulmonary disease risk: a meta-analysis.Genet Test Mol Biomarkers. 2013 Dec;17(12):910-7. doi: 10.1089/gtmb.2013.0308. Epub 2013 Oct 5.
563 Involvement of c-Jun N-Terminal Kinase in TNF--Driven Remodeling.Am J Respir Cell Mol Biol. 2017 Mar;56(3):393-401. doi: 10.1165/rcmb.2015-0195OC.
564 Upregulation of miR-132 contributes to the pathophysiology of COPD via targeting SOCS5.Exp Mol Pathol. 2018 Dec;105(3):285-292. doi: 10.1016/j.yexmp.2018.10.002. Epub 2018 Oct 4.
565 Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP.Hum Mol Genet. 2012 Mar 15;21(6):1325-35. doi: 10.1093/hmg/ddr569. Epub 2011 Dec 2.
566 Cigarette smoke modifies and inactivates SPLUNC1, leading to airway dehydration.FASEB J. 2018 Jun 11;32(12):fj201800345R. doi: 10.1096/fj.201800345R. Online ahead of print.
567 Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema.Am J Respir Cell Mol Biol. 2009 Sep;41(3):324-31. doi: 10.1165/rcmb.2008-0427OC. Epub 2009 Jan 8.
568 Comparative Study of Cytokine Levels in Different Respiratory Samples in Mild-to-Moderate AECOPD Patients.Lung. 2019 Oct;197(5):565-572. doi: 10.1007/s00408-019-00263-y. Epub 2019 Aug 26.
569 Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.PLoS Genet. 2016 Aug 17;12(8):e1006011. doi: 10.1371/journal.pgen.1006011. eCollection 2016 Aug.
570 CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling.Biomed Res Int. 2018 Jun 10;2018:3261436. doi: 10.1155/2018/3261436. eCollection 2018.
571 Targeted Sequencing of Lung Function Loci in Chronic Obstructive Pulmonary Disease Cases and Controls.PLoS One. 2017 Jan 23;12(1):e0170222. doi: 10.1371/journal.pone.0170222. eCollection 2017.
572 Atrophy and hypertrophy signalling of the quadriceps and diaphragm in COPD.Thorax. 2010 Nov;65(11):963-70. doi: 10.1136/thx.2009.133827.
573 Inflammatory and Immune Response Genes Polymorphisms are Associated with Susceptibility to Chronic Obstructive Pulmonary Disease in Tatars Population from Russia.Biochem Genet. 2016 Aug;54(4):388-412. doi: 10.1007/s10528-016-9726-0. Epub 2016 Mar 22.
574 External Validation Of The Updated ADO Score In COPD Patients From The Birmingham COPD Cohort.Int J Chron Obstruct Pulmon Dis. 2019 Oct 24;14:2395-2407. doi: 10.2147/COPD.S212381. eCollection 2019.
575 S-allylmercapto-l-cysteine modulates MUC5AC and AQP5 secretions in a COPD model via NF-B signaling pathway.Int Immunopharmacol. 2016 Oct;39:307-313. doi: 10.1016/j.intimp.2016.08.002. Epub 2016 Aug 9.
576 Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial.Age Ageing. 2018 Jan 1;47(1):82-88. doi: 10.1093/ageing/afx146.
577 Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease.Am J Respir Cell Mol Biol. 2015 Aug;53(2):226-34. doi: 10.1165/rcmb.2014-0198OC.
578 Increased rate of osteoporosis, low lean mass, and fragility fractures in COPD patients: association with disease severity.Osteoporos Int. 2018 Jun;29(6):1457-1468. doi: 10.1007/s00198-018-4483-z. Epub 2018 Mar 21.
579 Oxidative stress regulates autophagy in cultured muscle cells of patients with chronic obstructive pulmonary disease.J Cell Physiol. 2018 Dec;233(12):9629-9639. doi: 10.1002/jcp.26868. Epub 2018 Jun 26.
580 APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study.BMC Infect Dis. 2019 Feb 4;19(1):106. doi: 10.1186/s12879-019-3751-7.
581 Relationship between expression of matrix metalloproteinase-9 and adenylyl cyclase-associated protein 1 in chronic obstructive pulmonary disease.J Int Med Res. 2014 Dec;42(6):1272-84. doi: 10.1177/0300060514548290. Epub 2014 Oct 20.
582 [Resveratrol attenuates endoplasmic reticulum stress and alveolar epithelial apoptosis in a rat model of chronic obstructive pulmonary disease].Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jan;37(1):30-5.
583 Implication of C-type lectin receptor langerin and keratan sulfate disaccharide in emphysema.Cell Immunol. 2018 Nov;333:80-84. doi: 10.1016/j.cellimm.2018.07.004. Epub 2018 Jul 17.
584 Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease.Respir Res. 2014 Sep 21;15(1):113. doi: 10.1186/s12931-014-0113-2.
585 Characterization of adherence of nontypeable Haemophilus influenzae to human epithelial cells.Infect Immun. 2000 Aug;68(8):4658-65. doi: 10.1128/IAI.68.8.4658-4665.2000.
586 Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2019 Jul 22;14:1611-1631. doi: 10.2147/COPD.S184097. eCollection 2019.
587 Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists.J Pharmacol Exp Ther. 2011 Sep;338(3):860-9. doi: 10.1124/jpet.111.181016. Epub 2011 May 27.
588 Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.Respir Res. 2019 Oct 17;20(1):222. doi: 10.1186/s12931-019-1192-x.
589 Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1.J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):428-436. doi: 10.1002/jcsm.12171. Epub 2017 Jan 2.
590 Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer.Cancer Res. 2011 Apr 1;71(7):2572-81. doi: 10.1158/0008-5472.CAN-10-2046. Epub 2011 Feb 16.
591 The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD.Ann Med. 2019 Aug-Sep;51(5-6):314-329. doi: 10.1080/07853890.2019.1639809. Epub 2019 Jul 16.
592 Association between the p21 codon 31 A1 (arg) allele and lung cancer.Hum Hered. 1996 Jul-Aug;46(4):221-5. doi: 10.1159/000154357.
593 Krppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency.Orphanet J Rare Dis. 2012 May 23;7:29. doi: 10.1186/1750-1172-7-29.
594 Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease.Thorax. 2011 Dec;66(12):1085-90. doi: 10.1136/thoraxjnl-2011-200017. Epub 2011 Sep 15.
595 Using laser capture microdissection to study fiber specific signaling in locomotor muscle in COPD: A pilot study.Muscle Nerve. 2017 Jun;55(6):902-912. doi: 10.1002/mus.25423. Epub 2017 Feb 3.
596 PI3K/Akt-Nrf2 and Anti-Inflammation Effect of Macrolides in Chronic Obstructive Pulmonary Disease.Curr Drug Metab. 2019;20(4):301-304. doi: 10.2174/1389200220666190227224748.
597 Systematic Review and Meta-Analysis to Establish the Association of Common Genetic Variations in Vitamin D Binding Protein With Chronic Obstructive Pulmonary Disease.Front Genet. 2019 May 16;10:413. doi: 10.3389/fgene.2019.00413. eCollection 2019.
598 Reduced expression of growth differentiation factor 11 promoted the progression of chronic obstructive pulmonary disease by activating the AKT signaling pathway.Biomed Pharmacother. 2018 Jul;103:691-698. doi: 10.1016/j.biopha.2018.04.091. Epub 2018 Apr 24.
599 An Integrated Pan-Cancer Analysis and Structure-Based Virtual Screening of GPR15.Int J Mol Sci. 2019 Dec 10;20(24):6226. doi: 10.3390/ijms20246226.
600 Glutathione S-transferase M1 and T1 gene polymorphism and COPD risk in smokers: an updated analysis.Mol Biol Rep. 2012 Apr;39(4):5033-42. doi: 10.1007/s11033-011-1300-6. Epub 2011 Dec 9.
601 Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function.Antioxid Redox Signal. 2017 Sep 1;27(7):433-451. doi: 10.1089/ars.2016.6895. Epub 2017 Feb 7.
602 Chromosome 4q31 locus in COPD is also associated with lung cancer.Eur Respir J. 2010 Dec;36(6):1375-82. doi: 10.1183/09031936.00033310.
603 Genetic susceptibility to beryllium: a case-referent study of men and women of working age with sarcoidosis or other chronic lung disease.Occup Environ Med. 2015 Jan;72(1):21-7. doi: 10.1136/oemed-2014-102359. Epub 2014 Oct 10.
604 Rhinovirus and Bacteria Synergistically Induce IL-17C Release from Human Airway Epithelial Cells To Promote Neutrophil Recruitment.J Immunol. 2019 Jan 1;202(1):160-170. doi: 10.4049/jimmunol.1800547. Epub 2018 Nov 30.
605 Pharmacological Modulation of Endotoxin-Induced Release of IL-26 in Human Primary Lung Fibroblasts.Front Pharmacol. 2019 Aug 30;10:956. doi: 10.3389/fphar.2019.00956. eCollection 2019.
606 Risk of Severe Influenza Among Adults With Chronic Medical Conditions.J Infect Dis. 2020 Jan 2;221(2):183-190. doi: 10.1093/infdis/jiz570.
607 Notch promotes DNMT-mediated hypermethylation of Klotho leads to COPD-related inflammation.Exp Lung Res. 2018 Sep;44(7):368-377. doi: 10.1080/01902148.2018.1556749. Epub 2019 Jan 26.
608 Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways.Am J Respir Cell Mol Biol. 2008 Jun;38(6):679-88. doi: 10.1165/rcmb.2007-0282OC. Epub 2008 Jan 24.
609 A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6g and 160/18/9.6g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22.
610 LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.Front Immunol. 2019 Jan 29;10:6. doi: 10.3389/fimmu.2019.00006. eCollection 2019.
611 Genetic association analysis of functional impairment in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2006 May 1;173(9):977-84. doi: 10.1164/rccm.200509-1452OC. Epub 2006 Feb 2.
612 Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD.Eur Respir J. 2015 Jan;45(1):60-75. doi: 10.1183/09031936.00093314. Epub 2014 Sep 18.
613 Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.J Transl Med. 2017 Mar 24;15(1):65. doi: 10.1186/s12967-017-1168-x.
614 Matrix Metalloproteinase-28 Is a Key Contributor to Emphysema Pathogenesis.Am J Pathol. 2017 Jun;187(6):1288-1300. doi: 10.1016/j.ajpath.2017.02.008. Epub 2017 Apr 8.
615 The consequence of matrix dysfunction on lung immunity and the microbiome in COPD.Eur Respir Rev. 2018 Jun 27;27(148):180032. doi: 10.1183/16000617.0032-2018. Print 2018 Jun 30.
616 The C-terminal dimerization domain of the respiratory mucin MUC5B functions in mucin stability and intracellular packaging before secretion.J Biol Chem. 2019 Nov 8;294(45):17105-17116. doi: 10.1074/jbc.RA119.010771. Epub 2019 Sep 30.
617 Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease.Histopathology. 2004 Nov;45(5):477-84. doi: 10.1111/j.1365-2559.2004.01952.x.
618 NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.PLoS One. 2017 Jan 26;12(1):e0170606. doi: 10.1371/journal.pone.0170606. eCollection 2017.
619 Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.PLoS One. 2017 Nov 30;12(11):e0188716. doi: 10.1371/journal.pone.0188716. eCollection 2017.
620 Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis.Infect Immun. 1999 Sep;67(9):4578-85. doi: 10.1128/IAI.67.9.4578-4585.1999.
621 A polymorphism in ORMDL3 is associated not only with asthma without rhinitis but also with chronic obstructive pulmonary disease.J Investig Allergol Clin Immunol. 2013;23(4):256-61.
622 Expression Profile of Six RNA-Binding Proteins in Pulmonary Sarcoidosis.PLoS One. 2016 Aug 30;11(8):e0161669. doi: 10.1371/journal.pone.0161669. eCollection 2016.
623 PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).BMC Cancer. 2018 Dec 10;18(1):1238. doi: 10.1186/s12885-018-5140-9.
624 TGF-1 Impairs Vitamin D-Induced and Constitutive Airway Epithelial Host Defense Mechanisms.J Innate Immun. 2020;12(1):74-89. doi: 10.1159/000497415. Epub 2019 Apr 10.
625 PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.Autophagy. 2019 Mar;15(3):510-526. doi: 10.1080/15548627.2018.1532259. Epub 2018 Oct 13.
626 Ambient particulate matter attenuates Sirtuin1 and augments SREBP1-PIR axis to induce human pulmonary fibroblast inflammation: molecular mechanism of microenvironment associated with COPD.Aging (Albany NY). 2019 Jul 12;11(13):4654-4671. doi: 10.18632/aging.102077.
627 A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2005 Nov 1;172(9):1097-104. doi: 10.1164/rccm.200503-319OC. Epub 2005 Jul 7.
628 Analysis of global changes in gene expression induced by human polynucleotide phosphorylase (hPNPase(old-35)).J Cell Physiol. 2014 Dec;229(12):1952-62. doi: 10.1002/jcp.24645.
629 Total arch replacement versus debranching thoracic endovascular aortic repair for aortic arch aneurysm: what indicates a high-risk patient for arch repair in octogenarians?.Gen Thorac Cardiovasc Surg. 2018 May;66(5):263-269. doi: 10.1007/s11748-018-0894-1. Epub 2018 Jan 31.
630 Association of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection.Ann Thorac Cardiovasc Surg. 2018 Feb 20;24(1):13-18. doi: 10.5761/atcs.oa.17-00127. Epub 2017 Nov 10.
631 Circulating syndecan-1 as a novel biomarker relates to lung function, systemic inflammation, and exacerbation in COPD.Int J Chron Obstruct Pulmon Dis. 2019 Aug 28;14:1933-1941. doi: 10.2147/COPD.S207855. eCollection 2019.
632 Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer.J Cell Biochem. 2019 Nov;120(11):18724-18735. doi: 10.1002/jcb.29182. Epub 2019 Jun 20.
633 Downregulation of Sfrp5 in insulin resistant rats promotes macrophage-mediated pulmonary inflammation through activation of Wnt5a/JNK1 signaling.Biochem Biophys Res Commun. 2018 Oct 28;505(2):498-504. doi: 10.1016/j.bbrc.2018.09.070. Epub 2018 Sep 26.
634 Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency.Respirology. 2017 May;22(4):684-690. doi: 10.1111/resp.12952. Epub 2016 Nov 22.
635 Cordyceps sinensis inhibits airway remodeling in rats with chronic obstructive pulmonary disease.Exp Ther Med. 2018 Mar;15(3):2731-2738. doi: 10.3892/etm.2018.5777. Epub 2018 Jan 19.
636 miR-422a suppresses SMAD4 protein expression and promotes resistance to muscle loss.J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):119-128. doi: 10.1002/jcsm.12236. Epub 2017 Oct 6.
637 Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury.Am J Respir Cell Mol Biol. 2011 Mar;44(3):350-60. doi: 10.1165/rcmb.2009-0422OC. Epub 2010 May 6.
638 The copper-zinc superoxide dismutase activity in selected diseases.Eur J Clin Invest. 2019 Jan;49(1):e13036. doi: 10.1111/eci.13036. Epub 2018 Nov 6.
639 The protease inhibitor PI*S allele and COPD: a meta-analysis.Eur Respir J. 2005 Jul;26(1):67-76. doi: 10.1183/09031936.05.00135704.
640 Hypermethylation of mitochondrial transcription factor A induced by cigarette smoke is associated with chronic obstructive pulmonary disease.Exp Lung Res. 2019 Apr-May;45(3-4):101-111. doi: 10.1080/01902148.2018.1556748. Epub 2019 Jun 14.
641 Effect of TGF1 and TIMP2 on disease activity in asthma and COPD.Iran J Allergy Asthma Immunol. 2010 Jun;9(2):79-86.
642 Importance of mast cell Prss31/transmembrane tryptase/tryptase- in lung function and experimental chronic obstructive pulmonary disease and colitis.J Biol Chem. 2014 Jun 27;289(26):18214-27. doi: 10.1074/jbc.M114.548594. Epub 2014 May 12.
643 Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer.Am J Respir Cell Mol Biol. 2013 Sep;49(3):418-25. doi: 10.1165/rcmb.2012-0396OC.
644 SIRT1/FoxO3 axis alteration leads to aberrant immune responses in bronchial epithelial cells.J Cell Mol Med. 2018 Apr;22(4):2272-2282. doi: 10.1111/jcmm.13509. Epub 2018 Feb 7.
645 Correlation between lung cancer and the HHIP polymorphisms of chronic obstructive pulmonary disease (COPD) in the Chinese Han population.Genes Immun. 2019 Apr;20(4):273-280. doi: 10.1038/s41435-018-0033-0. Epub 2018 Jun 19.
646 Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways.J Allergy Clin Immunol. 2018 May;141(5):1634-1645.e5. doi: 10.1016/j.jaci.2017.08.017. Epub 2017 Sep 11.
647 Factors affecting the discharge of patients from hospital with seasonal influenza-the role of the Rapid Influenza testing in hospital discharges.Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):39-45. doi: 10.1007/s10096-019-03752-3. Epub 2019 Dec 3.
648 Relationship Between Circulating Serpina3g, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 and -2 with Chronic Obstructive Pulmonary Disease Severity.Biomolecules. 2019 Feb 13;9(2):62. doi: 10.3390/biom9020062.